AU2011317682A1 - Production of alkenes by combined enzymatic conversion of 3-hydroxyalkanoic acids - Google Patents
Production of alkenes by combined enzymatic conversion of 3-hydroxyalkanoic acidsInfo
- Publication number
- AU2011317682A1 AU2011317682A1 AU2011317682A AU2011317682A AU2011317682A1 AU 2011317682 A1 AU2011317682 A1 AU 2011317682A1 AU 2011317682 A AU2011317682 A AU 2011317682A AU 2011317682 A AU2011317682 A AU 2011317682A AU 2011317682 A1 AU2011317682 A1 AU 2011317682A1
- Authority
- AU
- Australia
- Prior art keywords
- amino acid
- acid sequence
- seq
- protein
- activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001336 alkenes Chemical class 0.000 title claims description 83
- 238000006243 chemical reaction Methods 0.000 title claims description 69
- 238000004519 manufacturing process Methods 0.000 title claims description 62
- 230000002255 enzymatic effect Effects 0.000 title description 12
- 239000002253 acid Substances 0.000 title description 6
- 150000007513 acids Chemical class 0.000 title description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 202
- 102000004190 Enzymes Human genes 0.000 claims description 180
- 108090000790 Enzymes Proteins 0.000 claims description 180
- 108090000623 proteins and genes Proteins 0.000 claims description 168
- 102000004169 proteins and genes Human genes 0.000 claims description 159
- 230000000694 effects Effects 0.000 claims description 88
- 230000000875 corresponding effect Effects 0.000 claims description 87
- VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical group CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 claims description 80
- 238000000034 method Methods 0.000 claims description 79
- 244000005700 microbiome Species 0.000 claims description 37
- 239000000758 substrate Substances 0.000 claims description 30
- -1 alkene compounds Chemical class 0.000 claims description 24
- 150000001875 compounds Chemical class 0.000 claims description 17
- 229910052799 carbon Inorganic materials 0.000 claims description 16
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 13
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 11
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 10
- 239000005977 Ethylene Substances 0.000 claims description 9
- 238000006114 decarboxylation reaction Methods 0.000 claims description 8
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 claims description 8
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 claims description 8
- BKOOMYPCSUNDGP-UHFFFAOYSA-N 2-methylbut-2-ene Chemical group CC=C(C)C BKOOMYPCSUNDGP-UHFFFAOYSA-N 0.000 claims description 7
- REKYPYSUBKSCAT-UHFFFAOYSA-N 3-hydroxypentanoic acid Chemical compound CCC(O)CC(O)=O REKYPYSUBKSCAT-UHFFFAOYSA-N 0.000 claims description 6
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 claims description 6
- WHBMMWSBFZVSSR-UHFFFAOYSA-M 3-hydroxybutyrate Chemical compound CC(O)CC([O-])=O WHBMMWSBFZVSSR-UHFFFAOYSA-M 0.000 claims description 5
- WHBMMWSBFZVSSR-UHFFFAOYSA-N R3HBA Natural products CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 claims description 5
- 239000001963 growth medium Substances 0.000 claims description 5
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 claims description 4
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 claims description 3
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 claims description 3
- 230000030609 dephosphorylation Effects 0.000 claims description 3
- 238000006209 dephosphorylation reaction Methods 0.000 claims description 3
- 235000011180 diphosphates Nutrition 0.000 claims description 3
- 238000000338 in vitro Methods 0.000 claims description 3
- 210000004671 cell-free system Anatomy 0.000 claims description 2
- 238000007872 degassing Methods 0.000 claims description 2
- 108090000489 Carboxy-Lyases Proteins 0.000 description 55
- 102000004031 Carboxy-Lyases Human genes 0.000 description 55
- SIGQQUBJQXSAMW-ZCFIWIBFSA-N (R)-5-diphosphomevalonic acid Chemical compound OC(=O)C[C@@](O)(C)CCOP(O)(=O)OP(O)(O)=O SIGQQUBJQXSAMW-ZCFIWIBFSA-N 0.000 description 54
- AXFYFNCPONWUHW-UHFFFAOYSA-N 3-hydroxyisovaleric acid Chemical compound CC(C)(O)CC(O)=O AXFYFNCPONWUHW-UHFFFAOYSA-N 0.000 description 20
- 238000003556 assay Methods 0.000 description 20
- 241000894006 Bacteria Species 0.000 description 16
- 241001632455 Picrophilus torridus Species 0.000 description 16
- 241000194026 Streptococcus gordonii Species 0.000 description 13
- 241001134658 Streptococcus mitis Species 0.000 description 12
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 8
- 230000037361 pathway Effects 0.000 description 8
- 229920000903 polyhydroxyalkanoate Polymers 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- 238000012216 screening Methods 0.000 description 8
- 241000196324 Embryophyta Species 0.000 description 7
- 230000003197 catalytic effect Effects 0.000 description 7
- 239000007789 gas Substances 0.000 description 7
- 229920003023 plastic Polymers 0.000 description 7
- 239000004033 plastic Substances 0.000 description 7
- 229920000070 poly-3-hydroxybutyrate Polymers 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 102000057412 Diphosphomevalonate decarboxylases Human genes 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- GWYFCOCPABKNJV-UHFFFAOYSA-M 3-Methylbutanoic acid Natural products CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 5
- 241000233866 Fungi Species 0.000 description 5
- 241000194017 Streptococcus Species 0.000 description 5
- 241001473878 Streptococcus infantarius Species 0.000 description 5
- 125000000217 alkyl group Chemical group 0.000 description 5
- 238000006911 enzymatic reaction Methods 0.000 description 5
- 239000000446 fuel Substances 0.000 description 5
- 239000007792 gaseous phase Substances 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- ALRHLSYJTWAHJZ-UHFFFAOYSA-M 3-hydroxypropionate Chemical compound OCCC([O-])=O ALRHLSYJTWAHJZ-UHFFFAOYSA-M 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 101000958922 Homo sapiens Diphosphomevalonate decarboxylase Proteins 0.000 description 4
- 101000958925 Panax ginseng Diphosphomevalonate decarboxylase 1 Proteins 0.000 description 4
- 108091000080 Phosphotransferase Proteins 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 238000004817 gas chromatography Methods 0.000 description 4
- 229930195733 hydrocarbon Natural products 0.000 description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 4
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 4
- 102000020233 phosphotransferase Human genes 0.000 description 4
- 150000003505 terpenes Chemical class 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- MHNNAWXXUZQSNM-UHFFFAOYSA-N 2-methylbut-1-ene Chemical compound CCC(C)=C MHNNAWXXUZQSNM-UHFFFAOYSA-N 0.000 description 3
- 241000194107 Bacillus megaterium Species 0.000 description 3
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- NHTMVDHEPJAVLT-UHFFFAOYSA-N Isooctane Chemical compound CC(C)CC(C)(C)C NHTMVDHEPJAVLT-UHFFFAOYSA-N 0.000 description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000004743 Polypropylene Substances 0.000 description 3
- 102000013009 Pyruvate Kinase Human genes 0.000 description 3
- 108020005115 Pyruvate Kinase Proteins 0.000 description 3
- 108091028733 RNTP Proteins 0.000 description 3
- 241000194022 Streptococcus sp. Species 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000002551 biofuel Substances 0.000 description 3
- 230000031018 biological processes and functions Effects 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- JVSWJIKNEAIKJW-UHFFFAOYSA-N dimethyl-hexane Natural products CCCCCC(C)C JVSWJIKNEAIKJW-UHFFFAOYSA-N 0.000 description 3
- 238000012239 gene modification Methods 0.000 description 3
- 230000005017 genetic modification Effects 0.000 description 3
- 235000013617 genetically modified food Nutrition 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 150000002430 hydrocarbons Chemical class 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- NUHSROFQTUXZQQ-UHFFFAOYSA-N isopentenyl diphosphate Chemical compound CC(=C)CCO[P@](O)(=O)OP(O)(O)=O NUHSROFQTUXZQQ-UHFFFAOYSA-N 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- YWAKXRMUMFPDSH-UHFFFAOYSA-N pentene Chemical group CCCC=C YWAKXRMUMFPDSH-UHFFFAOYSA-N 0.000 description 3
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 3
- 230000000243 photosynthetic effect Effects 0.000 description 3
- 239000005014 poly(hydroxyalkanoate) Substances 0.000 description 3
- 229920001155 polypropylene Polymers 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 238000003259 recombinant expression Methods 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 235000007586 terpenes Nutrition 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 3
- KJTLQQUUPVSXIM-ZCFIWIBFSA-N (R)-mevalonic acid Chemical compound OCC[C@](O)(C)CC(O)=O KJTLQQUUPVSXIM-ZCFIWIBFSA-N 0.000 description 2
- LIKMAJRDDDTEIG-UHFFFAOYSA-N 1-hexene Chemical compound CCCCC=C LIKMAJRDDDTEIG-UHFFFAOYSA-N 0.000 description 2
- ALRHLSYJTWAHJZ-UHFFFAOYSA-N 3-hydroxypropionic acid Chemical class OCCC(O)=O ALRHLSYJTWAHJZ-UHFFFAOYSA-N 0.000 description 2
- 241000203069 Archaea Species 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 241000252867 Cupriavidus metallidurans Species 0.000 description 2
- 241001149409 Cystobasidium minutum Species 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- KJTLQQUUPVSXIM-UHFFFAOYSA-N DL-mevalonic acid Natural products OCCC(O)(C)CC(O)=O KJTLQQUUPVSXIM-UHFFFAOYSA-N 0.000 description 2
- 101710183613 Diphosphomevalonate decarboxylase Proteins 0.000 description 2
- 241000588722 Escherichia Species 0.000 description 2
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 2
- 102100037759 GRB2-associated-binding protein 2 Human genes 0.000 description 2
- 101001024902 Homo sapiens GRB2-associated-binding protein 2 Proteins 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- 229910018828 PO3H2 Inorganic materials 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 229920000388 Polyphosphate Polymers 0.000 description 2
- 208000037534 Progressive hemifacial atrophy Diseases 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 241000193985 Streptococcus agalactiae Species 0.000 description 2
- 241001147754 Streptococcus gordonii str. Challis Species 0.000 description 2
- 241000327149 Streptococcus salivarius SK126 Species 0.000 description 2
- 241000557476 Streptococcus sanguinis SK36 Species 0.000 description 2
- 241000194021 Streptococcus suis Species 0.000 description 2
- 241000825101 Streptococcus suis 89/1591 Species 0.000 description 2
- 241000204673 Thermoplasma acidophilum Species 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 229920000704 biodegradable plastic Polymers 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000004523 catalytic cracking Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 239000013256 coordination polymer Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 229910000397 disodium phosphate Inorganic materials 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- OJDJHGIXNZPZFD-UHFFFAOYSA-N ethyl dihydrogen diphosphate Chemical compound CCO[P@](O)(=O)OP(O)(O)=O OJDJHGIXNZPZFD-UHFFFAOYSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 230000037353 metabolic pathway Effects 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- PRFDQHCVOVMMJC-UHFFFAOYSA-N methyl phosphono hydrogen phosphate Chemical compound COP(O)(=O)OP(O)(O)=O PRFDQHCVOVMMJC-UHFFFAOYSA-N 0.000 description 2
- ZGEGCLOFRBLKSE-UHFFFAOYSA-N methylene hexane Natural products CCCCCC=C ZGEGCLOFRBLKSE-UHFFFAOYSA-N 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 238000012017 passive hemagglutination assay Methods 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000003209 petroleum derivative Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 230000029553 photosynthesis Effects 0.000 description 2
- 238000010672 photosynthesis Methods 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 239000001205 polyphosphate Substances 0.000 description 2
- 235000011176 polyphosphates Nutrition 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- JCWMAIAFQQTSAX-UHFFFAOYSA-N propyl trihydrogen diphosphate Chemical compound CCCO[P@](O)(=O)OP(O)(O)=O JCWMAIAFQQTSAX-UHFFFAOYSA-N 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- VXNZUUAINFGPBY-UHFFFAOYSA-N 1-Butene Chemical compound CCC=C VXNZUUAINFGPBY-UHFFFAOYSA-N 0.000 description 1
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 1
- KEGHVPSZIWXTPY-UHFFFAOYSA-N 3-hydroxy-3-methylpentanoic acid Chemical compound CCC(C)(O)CC(O)=O KEGHVPSZIWXTPY-UHFFFAOYSA-N 0.000 description 1
- DFVOXRAAHOJJBN-UHFFFAOYSA-N 6-methylhept-1-ene Chemical compound CC(C)CCCC=C DFVOXRAAHOJJBN-UHFFFAOYSA-N 0.000 description 1
- 241000588986 Alcaligenes Species 0.000 description 1
- 241000219195 Arabidopsis thaliana Species 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000193749 Bacillus coagulans Species 0.000 description 1
- 241000604931 Bdellovibrio bacteriovorus Species 0.000 description 1
- 241000589968 Borrelia Species 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- KJQMOGOKAYDMOR-UHFFFAOYSA-N CC(=C)C=C.CC(=C)C=C Chemical compound CC(=C)C=C.CC(=C)C=C KJQMOGOKAYDMOR-UHFFFAOYSA-N 0.000 description 1
- 241001643775 Chloroflexus aggregans Species 0.000 description 1
- 241000192731 Chloroflexus aurantiacus Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 241000243212 Encephalitozoon cuniculi Species 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 241001070164 Enterococcus faecium TX1330 Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000589565 Flavobacterium Species 0.000 description 1
- 241000605108 Flavobacterium johnsoniae Species 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 241001152403 Haloquadratum walsbyi Species 0.000 description 1
- 229920002488 Hemicellulose Polymers 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- 240000001929 Lactobacillus brevis Species 0.000 description 1
- 235000013957 Lactobacillus brevis Nutrition 0.000 description 1
- 241000186673 Lactobacillus delbrueckii Species 0.000 description 1
- 241000186840 Lactobacillus fermentum Species 0.000 description 1
- 241000186869 Lactobacillus salivarius Species 0.000 description 1
- 241000589242 Legionella pneumophila Species 0.000 description 1
- 241000327151 Leptotrichia goodfellowii F0264 Species 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- 241000157876 Metallosphaera sedula Species 0.000 description 1
- 241000205274 Methanosarcina mazei Species 0.000 description 1
- HWZUDASOMGNLSM-UHFFFAOYSA-N O=P1OCOP(=O)O1 Chemical compound O=P1OCOP(=O)O1 HWZUDASOMGNLSM-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000063718 Picrophilus torridus DSM 9790 Species 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 241000235346 Schizosaccharomyces Species 0.000 description 1
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 241000191984 Staphylococcus haemolyticus Species 0.000 description 1
- 241001147691 Staphylococcus saprophyticus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241001540742 Streptococcus agalactiae NEM316 Species 0.000 description 1
- 241000194042 Streptococcus dysgalactiae Species 0.000 description 1
- 241000194048 Streptococcus equi Species 0.000 description 1
- 241001288016 Streptococcus gallolyticus Species 0.000 description 1
- 241001167808 Streptococcus gallolyticus UCN34 Species 0.000 description 1
- 244000057717 Streptococcus lactis Species 0.000 description 1
- 235000014897 Streptococcus lactis Nutrition 0.000 description 1
- 241001459892 Streptococcus mitis B6 Species 0.000 description 1
- 241001521783 Streptococcus mutans UA159 Species 0.000 description 1
- 241000224974 Streptococcus oralis ATCC 35037 Species 0.000 description 1
- 241000193991 Streptococcus parasanguinis Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 241000194023 Streptococcus sanguinis Species 0.000 description 1
- 241000194020 Streptococcus thermophilus Species 0.000 description 1
- 241000194054 Streptococcus uberis Species 0.000 description 1
- 241001624363 Streptococcus uberis 0140J Species 0.000 description 1
- 241000187180 Streptomyces sp. Species 0.000 description 1
- 241000204667 Thermoplasma Species 0.000 description 1
- 241000489996 Thermoplasma volcanium Species 0.000 description 1
- 241000589499 Thermus thermophilus Species 0.000 description 1
- 241000223259 Trichoderma Species 0.000 description 1
- 241000499912 Trichoderma reesei Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000009603 aerobic growth Effects 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229940054340 bacillus coagulans Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- IAQRGUVFOMOMEM-UHFFFAOYSA-N butene Natural products CC=CC IAQRGUVFOMOMEM-UHFFFAOYSA-N 0.000 description 1
- 150000001722 carbon compounds Chemical class 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000007806 chemical reaction intermediate Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 239000003245 coal Substances 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 229940032049 enterococcus faecalis Drugs 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000012262 fermentative production Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000003502 gasoline Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 150000002402 hexoses Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229910052816 inorganic phosphate Inorganic materials 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000002843 lactate dehydrogenase assay Methods 0.000 description 1
- 229940012969 lactobacillus fermentum Drugs 0.000 description 1
- 229940115932 legionella pneumophila Drugs 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229940102859 methylene diphosphonate Drugs 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 150000004712 monophosphates Chemical class 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000004817 pentamethylene group Chemical class [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 150000002972 pentoses Chemical class 0.000 description 1
- 239000003348 petrochemical agent Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229930029653 phosphoenolpyruvate Natural products 0.000 description 1
- DTBNBXWJWCWCIK-UHFFFAOYSA-N phosphoenolpyruvic acid Chemical compound OC(=O)C(=C)OP(O)(O)=O DTBNBXWJWCWCIK-UHFFFAOYSA-N 0.000 description 1
- 238000011197 physicochemical method Methods 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- HJHVQCXHVMGZNC-JCJNLNMISA-M sodium;(2z)-2-[(3r,4s,5s,8s,9s,10s,11r,13r,14s,16s)-16-acetyloxy-3,11-dihydroxy-4,8,10,14-tetramethyl-2,3,4,5,6,7,9,11,12,13,15,16-dodecahydro-1h-cyclopenta[a]phenanthren-17-ylidene]-6-methylhept-5-enoate Chemical compound [Na+].O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C([O-])=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C HJHVQCXHVMGZNC-JCJNLNMISA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 229940037649 staphylococcus haemolyticus Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229940115920 streptococcus dysgalactiae Drugs 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 229940115922 streptococcus uberis Drugs 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 239000000057 synthetic resin Substances 0.000 description 1
- 150000003509 tertiary alcohols Chemical class 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 241001624918 unidentified bacterium Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Description
PRODUCTION OF ALKENES BY COMBINED ENZYMATIC CONVERSION OF 3-
HYDROXYALKANOIC ACIDS
The present invention relates to a method for generating alkenes through a biological process. More specifically, the invention relates to a method for producing aikenes (for example propylene, ethylene, 1 -butylene, isobutylene or isoamylene) from molecules of the 3-hydroxyalkanoate type.
A large number of chemical compounds are currently derived from petrochemicals. Alkenes (such as ethylene, propylene, the different butenes, or else the pentenes, for example) are used in the plastics industry, for example for producing polypropylene or polyethylene, and in other areas of the chemical industry and that of fuels.
Ethylene, the simplest alkene, lies at the heart of industrial organic chemistry: it is the most widely produced organic compound in the world. It is used in particular to produce polyethylene, a major plastic. Ethylene can also be converted to many industrially useful products by reaction (of oxidation, of halogenation).
Propylene holds a similarly important role: its polymerization results in a plastic material, polypropylene. The technical properties of this product in terms of resistance, density, solidity, deformability, and transparency are unequalled. The worldwide production of polypropylene has grown continuously since its invention in 1954.
Butylene exists in four forms, one of which, isobutylene, enters into the composition of methy!-tert-butyl-ether (MTBE), an anti-knock additive for automobile fuel, isobutylene can also be used to produce isooctene, which in turn can be reduced to isooctane (2,2,4-trimethyipentane); the very high octane rating of isooctane makes it the best fuel for so-called "gasoline" engines.
Amylene, hexene and heptene exist in many forms according to the position and configuration of the double bond. These products have real industrial applications but are less important than ethylene, propylene or butenes.
All these alkenes are currently produced by catalytic cracking of petroleum products (or by a derivative of the Fisher-Tropsch process in the case of hexene, from coal or gas). Their cost is therefore naturally indexed to the price of oil. Moreover, catalytic
cracking is sometimes associated with considerable technical difficulties which increase process complexity and production costs.
Independently of the above considerations, the bioproduction of plastics ("bioplastics") is a thriving field. This boom is driven by economic concerns linked to the price of oil, and by environmental considerations that are both global (carbon- neutral products) and local (waste management).
The main family of bioplastics is that of the polyhydroxyalkanoat.es (PHA). These are polymers obtained by condensation of molecules comprising both an acid group and an alcohol group. Condensation takes place by esterification of the acid on the alcohol of the following monomer. This ester bond is not as stable as the direct parbon-carbon bond present in the polymers of conventional plastics, which explains why PHAs have a biodegradability of a few weeks to a few months.
The PHA family includes in particular poly-3-hydroxybutyrate (PHB), a polymer of 3- hydroxybutyrate, and poiyhydroxybutyrate-va!erate (PHBV), an alternating polymer of 3-hydroxybutyrate and 3-hydroxyvaierate.
PHB is naturally produced by some strains of bacteria such as Alcaligenes eutrophus and Bacillus megaterium. Laboratory bacteria, like E. coli, having integrated synthetic pathways leading to PHB or to PHAs in general, have been constructed. The compound or its polymer can, in certain laboratory conditions, account for up to 80% of the bacterial mass (Wong MS et al., Biotech. Bioeng.99 (2008), 919-928). Industrial-scale production of PHB was attempted in the 1980s, but the costs of producing the compound by fermentation were considered too high at the time. Projects involving the direct production of these compounds in genetically modified plants (having integrated the key enzymes of the PHB synthetic pathway present in producer bacteria) are in progress and might entail lower operating costs.
The biological production of aikanes or other hydrocarbon molecules that can be used as fuels or as precursors of synthetic resins is called for in the context of a sustainable industrial operation in harmony with geochemical cycles. The first generation of biofuels consisted in the fermentative production of ethanol, as fermentation and distillation processes already existed in the food processing industry. The production of second generation biofuels is in an exploratory phase, encompassing in particular the production of long chain alcohols (butanol and pentanol), terpenes, linear aikanes and fatty acids. Two recent reviews provide a general overview of research in this field: Ladygina N et a!., Process Biochemistry,
2006, 41 :1001 ; and Wackett LP, Current Opinions in Chemical Biology, 2008, 21 :187. in the aikene chemical family, isoprene (2-methyl-1 ,3-butadiene) is the terpene motif which, through polymerization, leads to rubber. Other terpenes might be developed, by chemical, biological or mixed pathways, as usable products such as biofuels or to manufacture plastics. The recent literature shows that the mevaionate pathway {a key intermediate in steroid biosynthesis in many organisms) might be used in order to efficiently produce products from the terpene family at industrial yields (Withers ST et al., Appl. Environ. Microbiol., 2007, 73:6277).
The production of alkenes, in particular terminal aikenes, [ethylene mono- or di~ substituted at position 2: H2C=C(R1)(R2)] has apparently been less extensively investigated. The conversion of isovalerate to isobutylene by the yeast Rhodotorula minuta has been described (Fujti T. et al., Appl. Environ. Microbiol., 1988, 54:583), but the efficiency of this reaction, characterized by a very low value of the turnover number (kcai is 1x10"5 sec " ), is far from permitting an industrial application. The reaction mechanism was elucidated by Fukuda H et al. (BBRC, 1994, 201 {2):516) and involves a cytochrome P450 enzyme which decarboxylates isovalerate by reduction of an oxoferryl group Fev=O. At no point does the reaction involve hydroxy!ation of isovalerate. Isovalerate is also an intermediate in leucine catabolism. Large-scale biosynthesis of isobutylene by this pathway seems highly unfavorable, since it would require the synthesis and degradation of one molecule of leucine to form one molecule of isobutylene. Also, the enzyme catalyzing the reaction uses heme as cofactor, poorly lending itself to recombinant expression in bacteria and to improvement of enzyme parameters. For all these reasons, it appears very unlikely that this pathway of the prior art can serve as a basis for industrial exploitation. Other microorganisms have been described as being marginally capable of naturally producing isobutylene from isovalerate; the yields obtained are even lower than those obtained with Rhodotorula minuta (Fukuda H. et al, Agric. Biol. Chem., 1984, 48:1679).
The same studies have also described the natural production of propylene: many microorganisms are capable of producing propylene, once again with an extremely low yield. The production of ethylene by plants has long been known (Meigh et al, 1960, Nature, 186:902). According to the metabolic pathway elucidated, methionine is the precursor of ethylene (Adams and Yang, PNAS, 1979, 76:170). Conversion of 2-oxoglutarate has also been described (Ladygina N et al., Process Biochemistry
2006, 41 :1001 ). Since the production of a two-carbon molecule of ethylene consumes a four- or five-carbon molecule precursor, these pathways appear materially and energetically unfavorable for their industrial application.
Thus, there is a need for efficient methods for producing alkenes such as ethylene, propylene, 1-butyiene, isobutylene, 1 -amylene or isoamylene.
WO2010/00 078 describes a process for producing alkenes by enzymatic conversion of 3-hydroxyalkanoic acids with an enzyme having the activity of a decarboxylase. Such a method is advantageous because it helps to avoid the use of petroleum products, to lower the costs of producing plastics and fuels and can have a considerable global environmental impact by allowing carbon to be stored in solid form. Although the method described in WO 2010/001078 allows to produce alkenes by enzymatically converting 3-hydroxyalkanoates, there is sti!l a need for improvements, in particular as regards efficiency of the process so as to make it suitable for industrial purposes. The present application addresses this need.
The present invention describes a method for producing alkene compounds starting from a 3-hydroxyalkanoate through a biological process, in particular an enzymatic process, in which two types of enzymes are combined in order to increase the efficiency of the production rate. More specifically, the present invention relates to a method for producing an alkene, characterized in that it comprises the conversion of a 3-hydroxyalkanoate into said alkene by
(i) a first enzyme having an activity of converting the 3-hydroxyalkanoate into the corresponding 3-phosphonoxyaikanoate; and
(ii) a second enzyme being different from the first enzyme and having an activity of converting said 3-phosphonoxyaikanoate into said alkene.
The present invention also relates to the use of at least two enzymes, wherein one enzyme is selected from (i) as specified above and the other enzyme is selected from (ii) as specified above or of a microorganism producing said combination of enzymes, for producing an alkene compound from a 3-hydroxyaikanoate.
The present invention also relates to organisms, preferably microorganisms, which produce at least two enzymes, wherein one enzyme is selected from (i) as specified above and the other enzyme is selected from (ii) as specified above,
"3-hydroxyalkanoate", as used herein, denotes a molecule responding to the following general formula:
Cn+1 Η2η+2θ3
, with 1 <n<7, and comprising 3-hydroxypropionate as a common motif (Figure 1 ), and optionally one or two alkyi substitutions on carbon 3. Said alkyl residues or groups can be linear or branched. As used herein, the terms "alkoyi" and "alkyl" have the same meaning and are interchangeable. Likewise, the terms "residue" and "group" have the same meaning and are interchangeable. Methyl, ethyl, propyl, isopropyl, butyl, isobutyl groups are examples of said alkyl groups. Carbon 3 becomes a chiral center if the two alkyl substitutions are different. The present definition encompasses the two chiral forms, even if one of the two forms, for example the R form, is the main form produced naturally. Examples of 3- hydroxyalkanoates are presented in Figure 3. Optionally, alkyl substituents can be added on carbon 2, which then may also become chiral (if the two substituents are different). Equally, the configurations of the 3-hydroxyalkanoate substrates in the present invention encompass all the stereoisomers. In a preferred embodiment, the 3-hydroxyalkanoates correspond either to 3-hydroxypropionate or to variants or derivatives of 3-hydroxypropionate in which one of the two or the two hydrogen atoms carried on carbon 3 are substituted by a motif composed solely of carbon and hydrogen atoms, the number of carbon atoms of said substituents ranging from 1 to 5, preferably from 1 to 3, such as methyl, ethyl, propyl, isopropyl, butyl or isobutyi. The suffix "oate", as used herein, can interchangeably denote either the carboxy!ate ion (COO-) or carboxylic acid (COOH). It is not used to denote an ester, in a particular embodiment, the 3-hydroxyalkanoates are represented by the following formula: HO-CO-CH2-C(R )(R2)-OH or O"-CO~CH2-C(R1){R2)-OH.
The term "3-phosphonoxyalkanoate" denotes a molecule which responds to the following general formula:
, with 1 <n<7, and comprising 3-phosphonoxypropionate as a common motif, and optionally one or two alkyl substitutions on carbon 3.
The term "alkene", as used herein, denotes molecules composed solely of carbon and hydrogen, containing one carbon-carbon double bond and having the chemical formula of a mono-unsaturated hydrocarbon, CnH2n> where n equals at least two. Preferably, n equals at least 3, 4, 5 or 6. Most preferably n is at most 6. Thus, generally, the term "alkene" refers to a molecule responding to the formula CnH2n, with 1 <n<7.
In a preferred embodiment alkenes are represented by the structural formula H2C=C{R1)(R2) wherein R1 and R2 are selected, independently, from the group consisting of a hydrogen atom and a linear or branched alkyl radical, so that the total number of carbon atoms in the alkene molecule is at most 6.
Preferred examples of alkene compounds according to the invention are in particular ethylene, propylene, isobutylene, and isoamylene (Figure 4), or else 1-butylene and 1-amylene.
"Carbon source", as used herein, denotes any carbon compound that can be used as substrate for the organisms according to the invention. Said term includes glucose or any other hexose, xylose or any other pentose, poiyols such as glycerol, sorbitol or mannitoi, or else polymers such as starch, cellulose or hemicellulose, or else poiy-3-hydroxyaikanoates like poly-3-hydroxybutyrate. It may be any substrate allowing the growth of microorganisms, such as formate for example. It may also be CO2 in the case where the organisms are capable of carrying out photosynthesis.
"Recombinant", as used herein, denotes the artificial genetic modification of an organism, either by addition, removal, or modification of a chromosomal or extra- chromosomal gene or regulatory motif such as a promoter, or by fusion of organisms, or by addition of a vector of any type, for example plasmidic. The term "recombinant expression" denotes the production of a protein involving a genetic modification, preferably in order to produce a protein of exogenous or heterologous origin with respect to its host, that is, which does not naturally occur in the production host, or in order to produce a modified or mutated endogenous protein.
"Overexpression" or "overexpressing", as used herein, denotes the recombinant expression of a protein in a host organism, preferably originating from an organism different from the one in which it is expressed, increased by at least 10% and preferably by 20%, 50%, 100%, 500% and possibly more as compared to the natural expression of said protein occurring in said host organism. This definition also encompasses the case where there is no natural expression of said protein.
A "co-substrate" is a compound or molecule added to the enzymatic reaction, so as to improve certain parameters thereof, and above all the activity thereof, said
product and the principal substrate being consumed in equal amounts. The co- substrate must therefore be added to the reaction at a concentration comparable to that of the principal substrate. Depending on the enzyme, the presence of a co- substrate may be required for the enzymatic reaction.
A "cofactor" is a product added to the enzymatic reaction, so as to improve certain parameters thereof and above all to improve the activity thereof, said product not being consumed during the reaction, and therefore needing only to be added at a low concentration, proportional to the amount of enzyme, said concentration therefore being referred to as "catalytic".
A "part" of an amino acid sequence denotes a fragment comprising at least 10, preferably at least 20, 30, 40 or 50 consecutive amino acid residues of said sequence.
"Homology", as used herein, denotes the existence of a similarity between two sequences as measured by the percent identity between said two sequences. In a preferred embodiment the term "homology" means sequence identity.
Chemical compounds are often known by several names, official or common. Herein, the common names of the molecules are preferred. Thus:
"ethylene" is used to denote ethene
"propylene" is used to denote propene
"butytene" is used to denote butene
"isobutySene" is used to denote 2-methylpropene or isobutene
"amylene" is used to denote pentene
"isoamylene" is used to denote 2-methyl-but-1-ene or isopentene
"propionate" is used to denote propanoic acid or the propanoate ion
"butyrate" is used to denote butanoic acid or the butanoate ion
"valerate" is used to denote pentanoic acid or the pentanoate ion.
The present invention describes a method for producing aikene compounds starting from a 3-hydroxya!kanoate through a biological process, in particular an enzymatic process, in which two types of enzymes are combined in order to increase the efficiency of the production rate. More specificaliy, the present invention relates to a method for producing an aikene, characterized in that it comprises the conversion of a 3-hydroxyalkanoate into said aikene by
(i) a first enzyme having an activity of converting the 3-hydroxyalkanoate into the corresponding 3-phosphonoxyalkanoate; and
(ii) a second enzyme being different from the first enzyme and having an activity of converting said 3-phosphonoxyalkanoate into said alkene.
As mentioned above, WO 2010/001078 describes a process for producing a!kenes by enzymatic conversion of 3-hydroxyalkanoic acids with an enzyme having the activity of a decarboxylase, tt has been described in WO 2010/001078 that generaliy the conversion of a 3-hydroxyalkanoate into an alkene by an enzyme having a decarboxylase activity, e.g. a mevalonate diphosphate (MDP) decarboxylase {E.C. 4.1 .1 .33) takes place by the conversion of the 3-hydroxyalkanoate into the corresponding 3-phosphonoxya!kanoate which is then decarboxylated to lead to the corresponding alkene. The generic reaction carried out by MDP decarboxylase using various 3-hydroxyalkanoates is depicted in Figure 2B.
It has now been found that different decarboxylases, in particular mevalonate diphosphate decarboxylases, catalyze the two above mentioned steps with different efficiencies, i.e. that some decarboxylases catalyze the first step with a higher efficiency than other decarboxylases and that some decarboxylases show a preference for the second step, i.e. the decarboxylation step, and that therefore the efficiency of the conversion of the 3-hydroxyalkanoate into the alkene as described in WO 2010/001078 can be significantly increased by combining corresponding enzymes. Thus, the present invention in particular relates to a method for achieving a higher efficiency in the enzymatic production of alkenes from 3-hydroxyalkanoates, i.e. a method for improving the efficiency of such an enzymatic production.
The term "an enzyme having an activity of converting the 3-hydroxyalkanoate into the corresponding 3-phosphonoxyalkanoate" means an enzyme which can phosphorylate a 3-hydroxyalkanoate into the corresponding 3- phosphonoxyalkanoate. The phosphate group comes preferably from an ATP molecule.
This activity can, e.g., be measured as described in the attached Examples, in particular Example 5. One possibility is thus to incubate the respective enzyme with the 3-hydroxyalkanoate and ATP and to measure the production of ADP (which reflects the production of the corresponding 3-phosphonoxyaikanoate). Assays for measuring the production of ADP are known to the person skilled in the art. One of these methods is the pyruvate kinase/lactate dehydrogenase assay described in Example 5. In this case the assay measures the rate of NADH absorbance decrease at 340 nm which is proportional to the ADP quantity. In a preferred embodiment the
term "an enzyme having an activity of converting the 3-hydroxyalkanoate into the corresponding 3-phosphonoxya!kanoate" means an enzyme which can convert 3- hydroxyisovalerate and ATP into 3-phosphonoxyisovalerate and ADP. Even more preferably such an enzyme can catalyze the reaction of converting the 3- hydroxya!kanoate into the corresponding 3-phosphonoxyalkanoate, preferably the reaction of converting 3-hydroxyisovalerate and ATP into 3-phosphonoxyssovalerate and ADP, with a KM of 10 mM or Iower, e.g. with a KM of 5 mM or Iower, preferably of 1 mM or Iower and even more preferably of 0.1 mM or Iower. in a particuiarly preferred embodiment such an enzyme can catalyze the reaction of converting the 3-hydroxyalkanoate into the corresponding 3-phosphonoxyalkanoate, preferably the reaction of converting 3-hydroxyisovaierate and ATP into 3-phosphonoxyisovalerate and ADP, with a kcat of at least 0.2 s"1 , preferably with a kcat of at least 0.5 s"\ particularly preferred with a kcat of at least 1 .0 s"1, more preferred of at least 2.0 s"1 and even more preferred with a kcat of at least 5.0 s"1.
In a particularly preferred embodiment the capacity to convert 3-hydroxyisovalerate and ATP into 3~phosphonoxyisovaierate and ADP is measured in an assay as described in Example 5.
The term "an enzyme having an activity of converting said 3-phosphonoxyalkanoate into said alkene" means an enzyme which can catalyze a reaction by which there is a decarboxylation and dephosporylation of the 3-phosphonoxyalkanoate thereby leading to the corresponding alkene.
This activity can, e.g., be measured as described in the appended Examples, in particular in Example 8. One possibility is thus to incubate the respective enzyme with the corresponding phosphonoxyalkanoate under conditions which in principle allow the decarboxylation and the dephosphory!ation and to detect the production of the corresponding alkene, e.g. by gas chromatography. In a preferred embodiment the term "an enzyme having an activity of converting said 3-phosphonoxyalkanoate into said alkene" means an enzyme which can convert 3-phosphonoxyisovaierate into isobutene, preferably under the conditions described in Example 8. Even more preferably such an enzyme can catalyze the reaction of converting the 3- phosphonoxyalkanoate into the corresponding alkene (via decarboxylation and dephosphorylation) with a KM of 100 mM or Iower, e.g. with a KM of 75 mM or Iower, or with a KM of 50 mM or Iower, preferably of 10 mM or Iower or 5 mM or Iower or 1 mM or Iower, and even more preferably of 0.1 mM or iower. In a particuiarly preferred embodiment such an enzyme can catalyze the reaction of converting the 3-phosphonoxyalkanoate into the corresponding alkene, preferably the reaction of
converting 3-phosphonoxyisovalerate into isobutene, with a kcat of at least 10"6 s" , preferably with a kcat of at least 10"4 s" , e.g. with a kcat of at least 10"3 s"1 or with a kcat of at least 10"2 s"1, such as with a kcat of at least 10"1 s"1 , for example with a kcat of at least 0.2 s"\ preferably with a kcat of at least 0.5 s" , particu!ariy preferred with a kcat of at least 1 .0
more preferred of at least 2.0 s" and even more preferred with a kcat of at least 5.0 s'
In a particularly preferred embodiment the capacity to convert 3- phosphonoxyisovalerate into isobutene is measured in an assay as described in Example 8.
In one preferred embodiment an enzyme mentioned in (i) and (ii), above, is an enzyme which is considered by NCBI or an equivalent engine as having a COG3407 domain.
In a preferred embodiment of the method according to the invention the first enzyme (i) having an activity of converting the 3-hydroxyalkanoate into the corresponding 3- phosphonoxyalkanoate is selected from the group consisting of
(A) a protein comprising the amino acid sequence as shown in SEQ ID NO: 1 or a protein comprising an amino acid sequence which is at least 15% identical to the amino acid sequence shown in SEQ ID NO: 1 and showing an activity of converting the 3-hydroxyaikanoate into the corresponding 3~ phosphonoxyalkanoate which is at least as high as the corresponding activity of the protein having the amino acid sequence shown in SEQ ID NO: 1 ;
(B) a protein comprising the amino acid sequence as shown in SEQ ID NO: 2 or a protein comprising an amino acid sequence which is at least 15% identical to the amino acid sequence shown in SEQ ID NO: 2 and showing an activity of converting the 3-hydroxya!kanoate into the corresponding 3- phosphonoxyalkanoate which is at least as high as the corresponding activity of the protein having the amino acid sequence shown in SEQ ID NO: 2;
(C) a protein comprising the amino acid sequence as shown in SEQ ID NO: 3 or a protein comprising an amino acid sequence which is at least 5% identical to the amino acid sequence shown in SEQ ID NO: 3 and showing an activity of converting the 3-hydroxyalkanoate into the corresponding 3- phosphonoxyatkanoate which is at least as high as the corresponding activity of the protein having the amino acid sequence shown in SEQ ID NO: 3; and
(D) a protein comprising the amino acid sequence as shown in SEQ ID NO: 4 or a protein comprising an amino acid sequence which is at least 15% identical to the
amino acid sequence shown in SEQ ID NO: 4 and showing an activity of converting the 3~hydroxyalkanoate into the corresponding 3- phosphonoxyalkanoate which is at least as high as the corresponding activity of the protein having the amino acid sequence shown in SEQ ID NO: 4.
SEQ ID NO: 1 shows the amino acid sequence of an enzyme from Picrophilus torridus DSM 9790 (GenBank accession number AAT43941 ; Swissprot/TrEMBL accession number Q6KZB1 ).
SEQ ID NO: 2 shows the amino acid sequence of an enzyme from Thermoplasma acidophilum (GenBank accession number CAC12426; Swissprot/TrEMBL accession number Q9HIN1 ).
SEQ ID NO: 3 shows the amino acid sequence of an enzyme from Thermoplasma volcanium (GenBank accession number BAB59465; Swissprot/TrEMBL accession number Q97BY2).
SEQ ID NO: 4 shows the amino acid sequence of an enzyme from Ferrop!asma acidarmanus ferl (GenBank accession number ZP_05571615).
In a further preferred embodiment of the method according to the invention the second enzyme (ii) having an activity of converting said 3-phosphonoxyalkanoate into said alkene is selected from the group consisting of
(a) a protein comprising the amino acid sequence as shown in SEQ ID NO: 5 or a protein comprising an amino acid sequence which is at least 15% identical to the amino acid sequence shown in SEQ ID NO: 5 and showing an activity of converting said 3-phosphonoxyalkanoate into said alkene which is at least as high as the corresponding activity of the protein having the amino acid sequence shown in SEQ ID NO: 5;
(b) a protein comprising the amino acid sequence as shown in SEQ ID NO: 6 or a protein comprising an amino acid sequence which is at least 15% identical to the amino acid sequence shown in SEQ ID NO: 6 and showing an activity of converting said 3-phosphonoxyalkanoate into said alkene which is at least as high as the corresponding activity of the protein having the amino acid sequence shown in SEQ ID NO: 6;
(c) a protein comprising the amino acid sequence as shown in SEQ ID NO: 7 or a protein comprising an amino acid sequence which is at least 15% identical to the amino acid sequence shown in SEQ ID NO: 7 and showing an activity of converting said 3-phosphonoxyalkanoate into said alkene which is at least as high as the corresponding activity of the protein having the amino acid sequence
11 shown in SEQ ID NO: 7;
(d) a protein comprising the amino acid sequence as shown in SEQ ID NO: 8 or a protein comprising an amino acid sequence which is at least 15% identical to the amino acid sequence shown in SEQ ID NO: 8 and showing an activity of converting said 3-phosphonoxyalkanoate into said alkene which is at least as high as the corresponding activity of the protein having the amino acid sequence shown in SEQ ID NO: 8;
(e) a protein comprising the amino acid sequence as shown in SEQ ID NO: 9 or a protein comprising an amino acid sequence which is at least 15% identical to the amino acid sequence shown in SEQ ID NO: 9 and showing an activity of converting said 3-phosphonoxyalkanoate into said alkene which is at least as high as the corresponding activity of the protein having the amino acid sequence shown in SEQ ID NO: 9;
(f) a protein comprising the amino acid sequence as shown in SEQ ID NO: 10 or a protein comprising an amino acid sequence which is at least 15% identical to the amino acid sequence shown in SEQ ID NO: 10 and showing an activity of converting said 3-phosphonoxyalkanoate into said alkene which is at least as high as the corresponding activity of the protein having the amino acid sequence shown in SEQ ID NO: 10;
(g) a protein comprising the amino acid sequence as shown in SEQ ID NO: 11 or a protein comprising an amino acid sequence which is at least 15% identical to the amino acid sequence shown in SEQ ID NO: 11 and showing an activity of converting said 3-phosphonoxyalkanoate into said alkene which is at least as high as the corresponding activity of the protein having the amino acid sequence shown in SEQ ID NO: 11 ;
(h) a protein comprising the amino acid sequence as shown in SEQ ID NO: 12 or a protein comprising an amino acid sequence which is at least 15% identical to the amino acid sequence shown in SEQ ID NO: 12 and showing an activity of converting said 3-phosphonoxyalkanoate into said a!kene which is at least as high as the corresponding activity of the protein having the amino acid sequence shown in SEQ ID NO: 12;
(i) a protein comprising the amino acid sequence as shown in SEQ ID NO: 13 or a protein comprising an amino acid sequence which is at least 15% identical to the amino acid sequence shown in SEQ ID NO: 13 and showing an activity of converting said 3-phosphonoxyaikanoate into said alkene which is at least as high as the corresponding activity of the protein having the amino acid sequence shown in SEQ ID NO: 13;
(j) a protein comprising the amino acid sequence as shown in SEQ !D NO: 14 or a protein comprising an amino acid sequence which is at least 15% identical to the amino acid sequence shown in SEQ ID NO: 14 and showing an activity of converting said 3-phosphonoxyalkanoate into said alkene which is at least as high as the corresponding activity of the protein having the amino acid sequence shown in SEQ ID NO: 14; and
(k) a protein comprising the amino acid sequence as shown in SEQ ID NO: 15 or a protein comprising an amino acid sequence which is at least 15% identical to the amino acid sequence shown in SEQ ID NO: 15 and showing an activity of converting said 3-phosphonoxyalkanoate into said alkene which is at least as high as the corresponding activity of the protein having the amino acid sequence shown in SEQ ID NO: 15.
SEQ ID NO: 5 shows the amino acid sequence of an enzyme cloned from Streptococcus gordonii. SEQ ID NO: 6 shows the amino acid sequence of an enzyme from Streptococcus gordonii str. Challis substr. CH1 {GenBank accession number AAT43941 ; Swissprot/TrEMBL accession number A8UU9). SEQ ID NO: 7 shows the amino acid sequence of an enzyme from Streptococcus infantarius subsp infantarius ATCC BAA-102 (GenBank accession number EDT48420.1 ; Swissprot/TrEMBL accession number B1 SCG0). SEQ ID NO: 8 shows the amino acid sequence of an enzyme from Homo sapiens (GenBank accession number AAC50440.1 ; Swissprot TrEMBL accession number P53602.1 ). SEQ ID NO: 9 shows the amino acid sequence of an enzyme from Lactobacillus delbrueckii (GenBank accession number CAI97800.1 ; Swissprot/TrEMBL accession number Q1 GAB2). SEQ ID NO: 10 shows the amino acid sequence of an enzyme from Streptococcus mitis (strain B6) (GenBank accession number CBJ22986.1 ). SEQ ID NO: 1 1 shows the amino acid sequence of an enzyme from Streptococcus gallo!yticus UCN34 (GenBank accession number CBM 3757.1 ). SEQ ID NO: 12 shows the amino acid sequence of an enzyme from Streptococcus sanguinis SK36 (GenBank accession number ABN43791.1 ). SEQ ID NO: 13 shows the amino acid sequence of an enzyme from Streptococcus sp. M143 (GenBank accession number EFA24040.1 ). SEQ ID NO: 14 shows the amino acid sequence of an enzyme from Streptococcus suis 89/1591 (GenBank accession number EEF63672.1 ). SEQ ID NO: 15 shows the amino acid sequence of an enzyme from Streptococcus salivarius SK126 (GenBank accession number EEK09252).
In a preferred embodiment of the method according to the invention the first enzyme
(i) is as defined in (A) above and the second enzyme (ii) is as defined in (a) or (b) mentioned above, even more preferably the second enzyme is as defined in (f), (g), (h), (i), (j) or (k) mentioned above. As illustrated in the examples, the combination of these enzymes is particularly efficient at producing alkene compounds according to the present invention.
In another preferred embodiment of the method according to the invention the second enzyme (ii) having an activity of converting said 3-phosphonoxyalkanoate into said alkene is selected from any one of the proteins listed in the following Table or from a protein comprising an amino acid sequence which is at least 15% identical to the amino acid sequence of such a protein and showing an activity of converting said 3-phosphonoxyalkanoate into said alkene which is at least as high as the corresponding activity of said protein.
Table 1
Ref sequence
Organism GenBank
Methanosarcina mazei AAM31457.1
Methanocaidococcus
jannaschii AAB98390.1
Staphylococcus saprophyticus BAE 19266.1
Streptococcus agalactiae EA073731 .1
Enterococcus faecalis AAO8071 1 .1
Flavobacterium johnsoniae ABQ04421 .1
Bdellovibrio bacteriovorus CAE79505.1
Chloroflexus aurantiacus A9WEU8.1
Legionella pneumophila CAH 13175.1
Listeria monocytogenes EAL09343.1
Metallosphaera sedula ABP95731.1
Staphylococcus epidermidis AAO03959.1
Streptococcus thermophilus AAV60266.1
Bacillus coagulans EAY45229.1
Chloroflexus aggregans EAV09355.1
Lactobacillus brevis ABJ64001 .1
Lactobacillus fermentum BAG27529.1
Lactobacillus piantarum CAD64155.1
Lactobacillus salivarius ABD99494.1
Lactococcus lactis sp. lactis AAK04503.1
Dicheiobacter nodosus ABQ14154.1
Flavobacterium psychrophiium CAL42423.1
Streptococcus pneumoniae EDT95457.1
Streptococcus pyogenes AAT86835.1
Streptococcus suis ABP91444.1
Staphylococcus haemolyticus BAE05710.1
Streptococcus equi ACG62435.1
Arabidopsis thaliana AAC67348.1
Borrelia afzeiii ABH01961.1
Encephalitozoon cuniculi CAD25409.1
Streptomyces sp. BAB07791 .1
Streptococcus agalactiae EA073731 .1
Streptococcus uberis CAR41735.1
Gallus gallus XP_423130
SaSmo saimar ACI34234
Natromonas pharaonis CAI48881.1
Haloarcu!a mansmortui AAV46412.1
Haloquadratum walsbyi CAJ51653.1
As mentioned above, not only the proteins having the specifically mentioned amino acid sequences listed in the respective SEQ ID NOs or in Table 1 can be used, but also proteins which are considered by NCBi or an equivalent engine as having a COG3407 domain and, more preferred, proteins the amino acid sequence of which shows a homology of at least 15% to the specifically mentioned amino acid sequence and which have a respective enzymatic activity at least as high as the activity of a protein having the specifically mentioned amino acid sequence. Preferred enzymes advantageously have at least x% homology, wherein x is selected from the group consisting of 20, 25, 20, 35, 40, 45, 50, 55 and 60. in a further preferred embodiment the enzyme has at least 65% sequence homology, preferably at least 70%, more preferably at least 75%, even more preferably, at least 80, 85, 90, 95, 96, 97, 98 or 99% homology to one of the sequences shown in SEQ ID NO: 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14 or 15 or to one of the sequences shown in Table 1. The percent of sequence homology can be determined by
different methods and by means of software programs known to one of skill in the art, such as for example the CLUSTAL method or BLAST and derived software, or by using a sequence comparison algorithm such as that described by Needleman and Wunsch (J. o!. Biol., 1970, 48:443) or Smith and Waterman (J. Mol. Biol., 1981 , 147:195).
Such proteins showing the indicated degree of homology can, e.g., be other enzymes which occur naturally or which have been prepared synthetically. They include in particular enzymes which can be selected for their ability to produce alkenes according to the invention. Thus, a selection test comprises contacting the purified enzyme, or a microorganism producing the enzyme, with the substrate of the reaction and measuring the production of the respective compound, i.e. the 3- phosphonoxyalkanoate or the aikene. Such tests are described in the experimental section. Such selection tests can also be used to screen for enzymes with an optimized enzymatic activity for the substrate to be converted into the 3- phosphonoxyalkanoate or the aikene, i.e. having an optimized activity with respect to one or more 3-hydroxyalkanoates or 3-phosphonoxyalkanoates.
Such screening methods are well-known in the art and include, e.g. protein engineering techniques such as random mutagenesis, massive mutagenesis, site- directed mutagenesis, DNA shuffling, synthetic shuffling, in vivo evolution, or complete synthesis of genes and subsequent screening for the desired enzymatic activity.
The enzyme used in the invention can thus be natural or synthetic, and produced by chemical, biological or genetic means. It can also be chemically modified, for example in order to improve its activity, resistance, specificity, purification, or to immobilize it on a support.
It has been found that enzymes which are able to catalyze the above described reactions for converting a 3-hydroxyalkanoate into an aikene via a 3-phospho- hydroxyalkanoate are often enzymes which can be classified in the phylogenetic superfamily of mevalonate diphosphate (MDP) decarboxylases (enzyme nomenclature EC 4.1 .1 .33). MDP decarboxylase is an enzyme involved in cholesterol biosynthesis. Said enzyme has been isolated from a variety of organisms including animals, fungi, yeasts and some bacteria. It can also be expressed by some plants (Lalitha et al., Phytochemistry 24 (1 1 ), (1985), 2569-2571 ). Many genes encoding this enzyme have been cloned and sequenced. These enzymes are generally composed of 300 to 400 amino acids and use ATP as co-substrate, which is converted during the reaction to ADP and inorganic phosphate. The phosphate group is transferred from the ATP molecule to the tertiary alcohol of mevalonate
diphosphate, releasing ADP. The reaction intermediate phosphorylated on the 3- hydroxyl group then undergoes elimination of the phosphate group, in the physiological case releasing isopentenyl diphosphate (Figure 2).
Accordingly, in a preferred embodiment, the enzyme defined in (i) or (ii) above, is a MDP decarboxylase. In the context of the present invention a MDP decarboxylase is defined as an enzyme which can at least catalyze the conversion of 5-diphospho-3- phosphomevalonate into isopentenyl-5-diphosphate and CO2 or which can at least catalyze the reaction of converting mevalonate diphosphate and ATP into 5- diphospho-3-phosphomevalonate and ADP. Preferably, such an enzyme can catalyze both reactions.
In another preferred embodiment the enzyme defined in (i) above, is an enzyme as defined in (i) (B). The sequence shown in SEQ ID NO: 2 represents an enzyme identified in Thermoplasma acidophilum. In Genbank this enzyme is classified as a mevalonate diphosphate decarboxylase. However, it is known from Chen and Poulter {Biochemistry 49 (2010), 207-217) that in Th. acidophilum there exists an alternative mevalonate pathway which involves the action of a mevalonate-5- monophosphate decarboxylase. Thus, it is possible that the enzyme represented by SEQ ID NO: 2 actually represents a mevalonate-5-monophosphate decarboxylase. The same may hold true for other archae bacteria. Therefore, in another preferred embodiment the enzyme defined in (i) or (ii) above, is a mevalonate-5- monophosphate decarboxylase. Such an enzyme is capable of converting mevalonate-5-monophosphate into isopentenylpyrophosphate.
In preferred embodiments of the invention:
3-hydroxypropionate is converted via 3-phosphonoxypropionate into ethylene; or
3-hydroxybutyrate is converted via 3-phosphonoxybutyrate into propylene; or 3-hydroxyvalerate is converted via 3-phosphonoxyvaierate into 1 -butylene; or 3-hydroxy-3-methyfbutyrate (or 3-hydroxyisovalerate) is converted via 3- phosphonoxy-3-methyibutyrate (3-phosphonoxyisovalerate) into isobutylene; or
3-hydroxy-3~methyivaierate is converted via 3-phosphonoxy-3-methylvalerate into isoamy!ene.
The method according to the invention can be carried out in vitro, in the presence of isolated enzymes (or enzyme systems additionally comprising one or more cofactors). In vitro preferably means in a cell-free system.
in one embodiment, the enzymes employed in the method are used in purified form to convert 3-hydroxyalkanoates to alkenes. However, such a method may be costly, since enzyme and substrate production and purification costs are high.
Thus, in another preferred embodiment, the enzymes employed in the method are present in the reaction as a non-purified extract, or else in the form of non-lysed bacteria, so as to economize on protein purification costs. However, the costs associated with such a method may still be quite high due to the costs of producing and purifying the substrates.
Accordingly, in one preferred embodiment, the enzymes, native or recombinant, purified or not, are used to convert a 3-hydroxyalkanoate to an alkene. To do this, the enzymes are incubated in the presence of the substrate in physicochemical conditions allowing the enzymes to be active, and the incubation is allowed to proceed for a sufficient period of time. At the end of the incubation, one optionally measures the presence of the alkene by using any detection system known to one of skill in the art such as gas chromatography or colorimetric tests for measuring the formation of the alkene product, or of free phosphate, or else for measuring the disappearance of the 3-hydroxyaikanoate substrate or of ATP.
In a preferred embodiment, cofactors are added so as to best mimic the natural reaction or so as to provide steric or electronic complementation in the catalytic cleft. For example, if one of the enzymes used in the method according to the invention is an enzyme which naturally uses mevalonate disphosphate (MDP) as a substrate, the structure of 3-hydroxyalkanoates leaves a large space in the catalytic cleft empty during enzyme-substrate binding since generally a 3-hydroxyalkanoate corresponds to a fragment of MDP. Filling this space with a cofactor to replace the missing part of the substrate has the purpose of most closely mimicking the MDP molecule. As the cofactor is not modified during the reaction, it will therefore be added only in catalytic amounts. In the case where the substrate of the reaction is 3-hydroxypropionate, the complementary cofactor will be propyl diphosphate. In the case where the substrate is 3-hydroxybutyrate or 3-hydroxy-3-methyibutyrate, the complementary cofactor will be ethyl diphosphate. In the case where the substrate is 3-hydroxyvalerate or 3- hydroxy-3-methylvalerate, the complementary cofactor will be methyl diphosphate. These different molecules are shown in Figure 5. By chance, it may happen that the complementary cofactor of a reaction has a positive effect on the reaction of another substrate. Generally, the cofactor can be any molecule comprising a phosphoanhydride, and therefore having the general global formula R-P02H-0-
PO3H2, in which R is in particular H, a linear, branched or cyclic alkyi group, preferably having from 1 to 10 or from 1 to 5 carbon atoms, or any other monovalent organic group. The analogous motifs corresponding to methylene diphosphonate monoesters, having the general formula R-O-PO2H-CH2-PO3H2 in which phosphyanhydride is replaced by a methylene bridge having the advantage of not being hydrolyzed, are also part of the invention. More generally, the cofactors can be monophosphate, or even phosphate-free, analogs of the previous molecules, or else any other molecule that can improve the reaction yield by providing steric or electronic complementation in the enzyme catalytic site. The cofactor is advantageously selected from the group consisting of the pyrophosphate ion, methyl diphosphate, ethyl diphosphate, or propyl diphosphate.
In a preferred embodiment, the conversion occurs in the presence of a co-substrate, said co-substrate preferably being a compound containing a phosphoanhydride, and preferably being ATP, an rNTP, a dNTP or a mixture of I of these molecules, a polyphosphate, or pyrophosphate. The co-substrate is generally present in the host. However, in another particular embodiment, a co-substrate can be added to the reaction, preferably selected from the group consisting of ATP, an rNTP, a dNTP, a mixture of several rNTPs or dNTPs, a polyphosphate, and preferably pyrophosphate, or a compound containing a phosphoanhydride (represented by the general formula X-P03H2 of Figure 2).
Although the decarboxylation step, i.e. the reaction defined as (ii) herein-above, does not require ATP consumption, it could be shown that the presence of ATP in the reaction could be beneficial. This has been demonstrated in Example 7, using 3- phosphonoxyisovalerate as a substrate. It is assumed that ATP might have an effect on the folding of the protein by the binding of ATP to the ATP-binding site of the diphosphomevalonate decarboxylase. In fact, this can be observed by eye: the purified enzyme has a tendency to precipitate, and the addition of ATP prevents this effect. It is considered that not only ATP but also other similar compounds like dATP, ADP, AMP or other NTPs or dNTPs have this effect. Thus, in a preferred embodiment, the method according to the present invention is carried with ATP, dATP, ADP, AMP or an NTP other than ATP or a dNTP as co-substrate.
In another preferred embodiment the method according to the invention is carried out in culture, in the presence of an organism, preferably a microorganism, producing the enzymes. Thus, in such an embodiment of the invention, an organism, preferably a microorganism, that produces the enzymes specified in (i) and (ii) above
is used. In a preferred embodiment, the (micro )organism is recombinant in that the enzymes specified in (i) and (ii) produced by the host are heterologous relative to the production host. The method can thus be carried out directly in the culture medium, without the need to separate or purify the enzymes. In an especially advantageous manner, a (micro )organism is used having the natural or artificial property of endogenously producing one or more 3-hydroxyaikanoates, and also expressing or overexpressing the enzymes specified in (i) and (ii) above, natural or modified, so as to produce alkenes directly from a carbon source present in solution.
For example, the method according to the invention can be carried out by using microorganisms which produce one or more 3-hydroxyalkanoates [for example Aica!igenes eutrophus or Bacillus megaterium, or else an E. coli strain genetically modified so as to produce said product(s)] and which have been genetically engineered such that they overexpress the enzymes as defined in (i) and (ii) above, said enzymes preferably originating from an organism different from the host microorganism. The genetic modification can consist, e.g. in integrating the corresponding genes encoding the enzymes into the chromosome, expressing the enzymes from a plasmid containing a promoter upstream of the enzyme-coding sequence, the promoter and coding sequence preferably originating from different organisms, or any other method known to one of skill in the art. Alternatively, other bacteria or yeasts may have specific advantages and can be chosen. For instance, a yeast such as Saccharomyces cerevisiae, an extremophilic bacterium such as Thermus thermophilus, or anaerobic bacteria from the family C!ostridiae, microalgae, or photosynthetic bacteria can be used.
The organisms used in the invention can be prokaryotes or eukaryotes, preferably, they are microorganisms such as bacteria, yeasts, fungi or molds, or plant cells or animal ceils. In a particular embodiment, the microorganisms are bacteria, preferably of the genus Escherichia, Alcaligenes or Bacillus and even more preferably of the species Escherichia coli, Alcaligenes eutrophus or Bacillus megaterium.
In another preferred embodiment, the microorganisms are recombinant bacteria of the genus Escherichia, preferably of the species Escherichia coli, having been modified so as to endogenously produce one or more 3-hydroxyaikanoates, and converting them to alkenes. in a further preferred embodiment the microorganism is a fungus, more preferably a fungus of the genus Saccharomyces, Schizosaccharomyces, Aspergillus or
Trichoderma and even more preferably of the species Saccharomyces cerevisiae, Schizosaccharomyces pombe, Aspergillus niger or of the species Trichoderma reesei. In a particuiariy preferred embodiment the microorganism is a recombinant yeast producing 3-hydroxyalkanoates and converting them to alkenes due to the expression of the enzymes specified in (i) and (ii) above.
In another preferred embodiment, the method according to the invention makes use of a photosynthetic microorganism expressing the enzymes as specified in (i) and (ii) above. Preferably, the microorganism is a photosynthetic bacterium, or a microalgae. Even more preferably such a microorganism has the natural or artificial property of endogenously producing one or more 3-hydroxyalkanoates. In this case the microorganism would be capable of producing alkenes directly from C02 present in solution.
It is also conceivable to use in the method according to the invention one microorganism that produces an enzyme as defined in (i) above and another microorganism which produces an enzyme as defined in (ii) above. Moreover, in a further embodiment at least one of the microorganisms is capable of producing one or more 3-hydroxya!kanoates or, in an alternative embodiment, a further microorganism is used in the method which is capable of producing one or more 3- hydrQxyalkanoai.es.
In another preferred embodiment the method according to the invention makes use of a multicellular organism expressing the enzymes as defined in (i) and (ii) above. Examples for such organisms are plants or animals.
In a particular embodiment, the method involves culturing microorganisms in standard culture conditions (30-37°C at 1 atm, in a fermenter allowing aerobic growth of the bacteria) or non-standard conditions (higher temperature to correspond to the culture conditions of thermophilic organisms, for example).
In a further preferred embodiment the method of the invention is carried out in microaerophilic conditions. This means that the quantity of injected air is limiting so as to minimize residual oxygen concentrations in the gaseous effluents containing the alkene hydrocarbons.
In another preferred embodiment the method according to the invention furthermore
comprises the step of collecting gaseous aikenes degassing out of the reaction, i.e. recovering the products which degas, e.g., out of the culture. Thus in a preferred embodiment, the method is carried out in the presence of a system for collecting alkene under gaseous form during the reaction.
As a matter of fact, short aikenes, and particularly ethylene, propylene and butene isomers, adopt the gaseous state at room temperature and atmospheric pressure. The method according to the invention therefore does not require extraction of the product from the liquid culture medium, a step which is always very costly when performed at industrial scale. The evacuation and storage of the gaseous hydrocarbons and their possible subsequent physical separation and chemical conversion can be performed according to any method known to one of skill in the art.
In a particular embodiment, the method also comprises detecting the alkene {for example propylene, ethylene or isobuty!ene) which is present in the gaseous phase. The presence of the compound to be produced in an environment of air or another gas, even in small amounts, can be detected by using various techniques and in particular by using gas chromatography systems with infrared or flame ionization detection, or by coupling with mass spectrometry.
In a particular embodiment, the aikenes produced by a method according to the invention are condensed, then optionally reduced, by using techniques known to one of skill in the art, so as to produce longer chain aikenes, or longer chain alkanes. For example, isobutylene can be used to synthesize isooctane: the catalytic methods for successfully carrying out this reaction have already been fully described.
In another embodiment, the method according to the invention is characterized by the conversion of a carbon source such as glucose, to 3-hydroxyalkanoate, followed by the conversion of said 3-hydroxyalkanoate into the corresponding alkene. The different steps of said method are outlined in Figure 6.
In a particular embodiment, the method is characterized by the conversion of polyhydroxyalkanoates into 3-hydroxyalkanoate by using an enzyme or a suitable physicochemical method, followed by the conversion of said 3-hydroxyalkanoate into said alkene. Optionally, the polyhydroxyalkanoate has been produced by a microorganism or a plant whose metabolic pathways have been modified to as to produce high yields of polyhydroxyalkanoate.
In another embodiment, the method according to the invention comprises the production of aikenes from atmospheric CO2 or from CO2 artificially added to the
culture medium, in this case the method is implemented in an organism which is able to carry out photosynthesis, such as for example microalgae.
The present invention also relates to a method for producing an alkene comprising the step of enzymatically converting a 3-phosphonoxyalkanoate into the corresponding alkene by use of an enzyme which can catalyze the conversion via decarboxylation and dephosphorylation.
As regards the preferred enzyme to be used in such a method, the same applies as has been set forth above in connection with (ii) of the method according to the invention as described herein-above.
Moreover, also with respect to the other preferred embodiments described above for the method according to the invention, the same applies to the method for producing an alkene from a 3-phosphonoxyalkanoate.
The present invention also relates to organisms, preferably microorganisms, which produce at least two enzymes, wherein one enzyme is selected from (i) as specified above and the other enzyme is selected from (ii) as specified above. In a preferred embodiment such an organism is a recombinant organism in the sense that it is genetically modified due to the introduction of at least one nucleic acid molecule encoding at least one of the above mentioned enzymes. Preferably such a nucleic acid molecule is heterologous with regard to the organism which means that it does not naturally occur in said organism.
Thus, the present invention also relates to an organism, preferably a microorganism, comprising a nucleic acid molecule coding for an enzyme as defined in (i) above and comprising a nucleic acid molecule coding for an enzyme as defined in (ii) above. In a preferred embodiment at least one of the nucleic acid molecules is heterologous to the organism which means that it does not naturally occur in said organism. The microorganism is preferably a bacterium, a yeast or a fungus. In another preferred embodiment the organism is a plant or non-human animal. As regards other preferred embodiments, the same applies as has been set forth above in connection with the method according to the invention.
Moreover, the present invention also relates to a composition comprising a microorganism according to the present invention, a suitable culture medium and a 3-hydroxyalkanoate compound or a carbon source that can be converted by the microorganism to a 3-hydroxyalkanoate compound.
The present invention also relates to the use of a combination of at least two enzymes, wherein one enzyme is selected from the following (i) and the other enzyme is selected from the following (ii) or of an organism, preferably a microorganism, according to the invention or of a composition according to the invention for producing alkene compounds from 3-hydroxyalkanoates, wherein (i) and (ii) are as follows:
(i) a first enzyme having an activity of converting the 3-hydroxyaikanoate into the corresponding 3-phosphonoxyalkanoate; and
(ii) a second enzyme being different from the first enzyme and having an activity of converting said 3-phosphonoxyaikanoate into said alkene.
As regards the preferred embodiments of the different components recited, the same applies as has been set forth above in connection with the method according to the invention.
Other aspects and advantages of the invention will be described in the following examples, which are given for purposes of illustration and not by way of limitation.
Figures legends
Figure 1 : The 3-hydroxypropionate motif.
Figure 2: Reaction catalyzed by mevalonate diphosphate decarboxylase.
Figure 3; Examples of 3-hydroxyalkanoates.
Figure 4: Production of alkenes from 3-hydroxyaikanoates by combining two enzymatic steps.
Figure 5: Cofactors that can be used in the reaction for the purpose of structural complementation in the catalytic site of mevalonate diphosphate decarboxylase.
Figure 6: Integrated method for producing an alkene from glucose.
Figure 7: Screening of MDP decarboxylases in a complementation assay. The reaction catalyzed by the P. torridus enzyme alone (0.1 mg) without a second enzyme, was taken as reference.
Figure 8: Combined effect of MDP decarboxylase enzymes from P. torridus and
S. gordonii for converting 3-hydroxyisovalerate (HIV) into isobutene (SBN). !BN production was measured as a function of the concentration
of S. gordonii MDP decarboxylase added to a pre-incubated reaction mixture of HIV with 100 pg of P. torridus MDP decarboxylase.
Figure 9: Screening of enzyme homologs of S. gordonii MDP decarboxylase. The peak area of isobutene obtained for the reaction with Th. acidophilum (0.1 mg) enzyme alone (no second enzyme), was used as reference (ratio=1 ).
MDP decarboxylases from the Streptococcus genus are particularly efficient when used in combination with an enzyme of the P. torridus phylum.
Figure 10: Scheme of the ADP quantification assay, monitoring NADH consumption by the decrease of absorbance at 340 nm.
Figure 1 1 : Plot of the velocity as a function of substrate concentration for the phosphotransferase reaction catalyzed by P. torridus MDP decarboxylase. Initial rates were computed from the kinetics over the 30 first minutes of the reaction.
Figure 12: isobutene production from 3-hydroxyisovaierate in the following assays:
Without enzyme
In the presence of S. mitis MDP decarboxylase
In the presence of Th. acidophiium MDP decarboxylase
In the presence of both Th. acidophilum and S. mitis enzymes.
Figure 13: Scheme for the chemical synthesis of 3-phosphonoxyisovalerate.
Figure 14: GC analysis of assays for isobutene production from 3- phosphonoxyisova!erate in the absence and presence of ATP.
Assays:
1. Without enzyme, 0 mM ATP
2. 2 mg/ml enzyme, 0 mM ATP
3. Without enzyme, 10 mM ATP
4. 2 mg/ml enzyme, 10 mM ATP
The following Examples serve to illustrate the invention.
Examples
Example 1 : Cloning, expression and purification of an MDP decarboxylase library.
A library of 55 genes encoding representatives of the diphosphomevalonate decarboxylase (MDP decarboxylase) family across eukaryotic, prokaryotic and archaea! organisms was constructed and tested to identify the most active candidates for improving isobutene (IBN) production.
Cloning, bacterial cultures and expression of proteins.
The genes encoding mevalonate diphosphate (MDP) decarboxylase EC 4.1 .1 .33 were cloned in the pET 25b vector (Novagen) in the case of eukaryotic genes and in pET 22b (Novagen) in the case of prokaryotic genes. A stretch of 6 histidine codons was inserted after the methionine initiation codon to provide an affinity tag for purification. Competent E. coli BL21 (DE3) cells (Novagen) were transformed with these vectors according to the heat shock procedure. The transformed cells were grown with shaking (160 rpm) on ZYM-5052 auto-induction medium (Studier FW, Prot.Exp.Pur. 41 , (2005), 207-234) for 6h at 37°C and protein expression was continued at 28°C overnight (approximately 16 h). The cells were collected by centrifugation at 4°C, 10,000 rpm for 20 min and the pellets were frozen at -80°C. Protein purification and concentration.
The pellets from 200 ml of culture cells were thawed on ice and resuspended in 5 ml of Na2HP04 pH 8 containing 300 mM NaCI, 5 mM MgCI2 and 1 mM DTT. Twenty microliters of !ysonase (Novagen) were added. Cells were incubated 10 minutes at room temperature and then returned to ice for 20 minutes. Cell lysis was completed by sonication for 3 x 15 seconds. The bacterial extracts were then clarified by centrifugation at 4°C, 10,000 rpm for 20 min. The clarified bacterial lysates were loaded on PROTINO-1000 Ni-TED column (Macherey-Nagel) allowing adsorption of 6-His tagged proteins. Columns were washed and the enzymes of interest were eluted with 4 mi of 50 mM Na2HP04 pH 8 containing 300 mM NaCI, 5 mM MgCI2, 1 mM DTT, 250 mM imidazole. Eluates were then concentrated and desalted on Amicon Ultra-4 10 kDa filter unit (Millipore) and resuspended in 0.25 mi 50 mM Tris- HCI pH 7.4 containing 0.5 mM DTT and 5 mM MgCi2- Protein concentrations were quantified according to the Bradford method. The purity of proteins thus purified
varied from 40 % to 90 %.
Example 2: Screening of the MDP decarboxylase library.
MDP decarboxylases were evaluated using a complementation assay. P. torridus MDP decarboxylase was incubated together with each tested enzyme from the library.
The enzymatic assay was carried out under the following conditions:
50 mM Tris HC1 pH 7,0
10 mM MgCI2
20 mM KCI
40 mM ATP
50 mM 3-hydroxyisovaierate (HIV)
The pH was adjusted to 7.0
100 pg of the MDP decarboxylase from P. torridus and 1 mg of the MDP decarboxylase to be tested were added to 1 ml of reaction mixture. A reaction mixture containing only 100 pg of P. torridus MDP decarboxylase was used as reference. The mixture was then incubated without shaking at 45°C for 90h in a sealed vial (Interchim).
One ml of the gaseous phase was coilected and injected into a HP5890 gas chromatograph (HP) equipped with an FID detector and a CP SilicaPlot column (Varian). Commercial isobutene was used as reference.
This screening procedure led to the identification of several MDP decarboxylase enzymes increasing the isobutene production rate. As shown in Figure 7, a higher production of isobutene was observed for the following MDP decarboxylases.
Candidate 1 :
Accession number Genbank : CA197800
Accession number SwissProt TrEMBL : Q1 GAB2
Organism: Lactobacillus deibrueckii subsp. bulgaricus ATCC 1 842
Candidate 2:
Accession number Genbank : AAC50440.1
Accession number SwissProt/TrEMBL : P53602.1
Organism: Homo sapiens
Candidate 3:
Accession number Genbank : ABV09606
Accession number SwissProt TrEMBL : A8AUU9
Organism: Streptococcus gordonii str. Challis substr. CH1
The highest production of isobutene was observed with purified MDP decarboxylase from Streptococcus gordonii.
This indicated that the two enzymes present in the assay {the one from P. torridus and the other from S. gordonii) were performing complementaniy the two steps of reaction producing !BN from HIV: transfer of the terminal phosphoryl group from ATP to the C3-oxygen of 3-hydroxyisovaierate followed by combined dephosphoryiation-decarboxylation of the intermediate 3-phosphonoxyisovalerate.
Example 3: Effect of enzyme concentration on isobutene production yield.
The effect of Streptococcus gordonii MDP decarboxylase concentration was assessed under the following conditions:
50 mM Tris-HCI pH 7,0
10 mM MgCI2
20 mM KCi
40 mM ATP
50 mM 3-hydroxyisovalerate (HIV)
The pH was adjusted to 7,0
100 pg of MDP decarboxylase from P. torridus and a varying amount (from 0 to 1 mg) of purified MDP decarboxylase from Streptococcus gordonii were added to 1 m! of reaction mixture. The mixture was then incubated without shaking at 45°C for 90h
in a sealed vial (Interchim).
One ml of the headspace phase was collected and injected into a HP5890 gas chromatograph (HP) equipped with an FID detector and a CP SiiicaP!ot column (Varian). Commercial isobutene was used as reference.
Increasing the S. gordonii enzyme concentration resulted in an increase of the amount of isobutene produced (Figure 8).
Example 4: Screening of a library of Streptococcus gordonii MDP decarboxylase homologs.
Using the BLAST online program hosted by NCBI, sequences were searched against non redundant protein sequence database to generate a list of enzymes with high sequence similarity (> 40% identity) to the Streptococcus gordonii enzyme. The resulting list included 18 candidates.
Microorganisms % Identity Accession
with MDP number Genbank decarboxyias
e from
Streptococcu
s gordonii
Streptococcus oralis ATCC 35037 75 EFE56694.1
Leptotrichia goodfellowii F0264 61 EEY36155.1
C a rno bacterium sp. AT7 40 EDP67928.1
Enterococcus faecium TX1330 40 EEI60970.1
Staphylococcus aureus JH1 40 ABR51487.1
Streptococcus agalactiae NEM316 70 CAD47054.1
Streptococcus mutans UA159 AAN58642.1
Streptococcus uberis 0140 J 71 CAR41735.1
Streptococcus infantarius subsp 71 EDT48420.1
infantarius ATCC BAA-102
Streptococcus gallolyticus UCN34 CBI13757.1
Streptococcus dysgalactiae subsp 71 BAH81333.1 equisimilis GGS_124
Streptococcus sp. M143 76 EFA24040.1
Streptococcus salivarius SK126 74 EEK09252.1
Streptococcus suis 89/1591 40 EEF63672.1
Streptococcus parasanguinis ATCC 73 EFH19018.1
15912
Streptococcus sanguinis SK36 98 ABN43791 .1
Streptococcus sp. 2_1_36FAA 98 EEY81027.1
Streptococcus mitis B6 74 CBJ22986.1
Sequences of MDP decarboxylase enzymes inferred from the genomes of the above species as well as from the genome of S. gordonii were generated by oligonucleotide concatenation to fit the codon usage of E. coli. A stretch of 6 histidine codons was inserted after the methionine initiation codon to provide an affinity tag for purification. The genes thus synthesized were cloned in a pET25b expression vector (the vectors were constructed by GENEART AG). After transformation of the E. coli strain BL21 (DE3), the proteins were produced according to the protocol described in Example 1 . The enzymes were then assayed using the method described in Example 2, using Th. acidophilum MDP decarboxylase instead of the P. torridus enzyme. This screening procedure led to the identification of enzymes more efficient for isobutene production than the S. gordonii enzyme (Figure 9), in particular MDP decarboxylases from S. infantarius, S. gallolyticus, S. sp. M143, S. saiivarius, S. suis, S. sanguinis and S. mitis.
Example 5: Characterisation of the phosphotransferase activity.
The release of ADP that is associated with !BN production from HIV was quantified using the pyruvate kinase/!actate dehydrogenase coupled assay (Figure 10). The
MDP decarboxylases from P. torridus, Th. acidophiium, S. infantarius, S. mitis were evaluated for their ability to phoshorylate HIV, releasing ADP.
The studied enzymatic reaction was carried out under the following conditions at
40°C:
50 mM Tris-HCI pH 7,0
10 mM MgCi2
lOO mM KCI
5 mM ATP
0,2 mM NADH
0,5 mM Phosphoenolpyruvate
3 U/ml Lactate dehydrogenase
1 ,5 U/ml Pyruvate kinase
0-50 mM 3-Hydroxyisovalerate (HIV)
The pH was adjusted to 7,0
Each assay was started by addition of particular enzyme (at a concentration from 0.05 to 1 mg/m!) and the disappearance of NADH was monitored by following the absorbance at 340 nM.
Assays with MDP decarboxylases from the P. torridus phylum as well from the Streptococcus genus gave rise to a reproducible increase in ADP production in the presence of HIV. Figure 1 1 shows an example of a Michaelis-Menten plot corresponding to the data collected for P. torridus enzyme. The kinetic parameters are shown in the following Table.
The enzymes from the P. torridus phylum displayed higher phosphotransferase
Organism KM, mM ^cat, S6C kCAT/ KM x Wz, mM"1 sec"1
Thermoplasma acidophiium 4.02 0.26 60
Picrophilus torridus 9.17 0.19 20
Streptococcus mitis 12.1 0.04 3
Streptococcus infantarius 13.4 0.03 2
activities than those of the Streptococcus genus.
Example 6: Isobutene production from 3-hydroxyisovalerate by combining two enzymes.
The desired enzymatic reaction was carried out under the foliowing conditions:
50 mM Tris HCt pH 7,5
10 mM MgCI2
20 mM KCI
40 mM ATP
50 mM HIV
The pH was adjusted to 7,5
100 pg of MDP decarboxylase from Th. acidophilum and 500 pg of MDP decarboxylase from S. mitis were added to 1 ml of reaction mixture. Control reactions with only one of the two enzymes were run in parallel. The assays were incubated without shaking at 37°C in a sealed vial (Interchim).
The production of IBN was measured by analyzing aliquots sampled over a 142 hour incubation period.
One ml of the gaseous phase was collected and injected into a HP5890 gas chromatograph (HP) equipped with an FID detector and a CP Si!icaPlot column (Varian). Commercial isobutene was used as reference.
The kinetics of isobutene production is shown in Figure 12. MDP decarboxylase from Th. acidophilum catalyzed the production of isobutene from HIV. The addition of MDP decarboxylase from S. mitis led to a 3-fold increase of isobutene production after 142 h of incubation.
MDP decarboxylase from S. mitis alone produced only small amounts of isobutene after 6 days of incubation, indicating a low phosphotransferase activity.
isobutene production can thus be increased by combining two types of enzymes performing complementarily the two reaction steps.
Example 7: Effect of ATP on isobutene production from 3- phosphonoxyisovaierate (PIV).
The compound 3-phosphonoxyisovalerate (PiV) was chemically synthesized from 3- hydroxyisovalerate according to the scheme depicted in Figure 13 by SYNTHEVAL (France).
The assays of isobutene production were carried out under the following conditions: 50 mM Tris-HC! pH 7,5
10 mM MgCI2
20 mM KCI
0 mM ATP (assay s1 and N°2)
10 mM ATP (assay N°3 and N°4)
25 mM 3-phosphonoxyisovalerate
The pH was adjusted to 7.5
The reaction was initiated by addition of 2 mg of purified MDP decarboxylase from S. mitis to 0.5 ml of reaction mixture. Control reactions were run in the absence of enzyme (assays N°1 and Ns3).
The mixture was incubated without shaking at 37°C for 26 h in a sealed vial of 2 ml (tnterchim).
One m! of the gaseous phase was collected and injected into a Varian 430-GC gas chromatograph equipped with an FID detector and a CP SiiicaPlot column (Varian). Commercial isobutene was used as reference.
Addition of 10 mM ATP to the reaction mixture increased 120 fold isobutene production from 3-phosphonoxyisovalerate (PIV) (Figure 14).
Example 8; Kinetic parameters of isobutene production from 3- phosphonoxyisova!erate (PIV).
The kinetic parameters of isobutene production were measured under the following conditions:
50 mM Tris-HCI pH 7,5
0 mM MgCI2
50 mM KCI
40 mM ATP
0-100 mM 3-phosphonoxyisovalerate
The pH was adjusted to 7,5
The reaction was initiated by addition of 1 rng of purified MDP decarboxylase from S, mitis to 0.5 mi of reaction mixture. The mixture was then incubated without shaking at 37°C for 44 h in a sealed vial of 2 ml (Interchim).
One mi of the gaseous phase was coilected and injected into a Varian 430-GC gas chromatograph equipped with an F!D detector and a CP Si!icaPlot column (Varian). Commercial isobutene was used as reference.
The assays with MDP decarboxylase from S. mitis showed a 160-400 fold increase in IBN production over the background level (spontaneous decomposition of 3- phosphonoxyisovalerate) in the presence of ATP as co-factor (see the following Table).
MDP decarboxylase from S. mitis was found to have a KM higher than 60 mM and a /(cat of at least 1 .3 x 10"3 sec"1.
Claims
Claims
A method for producing an alkene, characterized in that it comprises the conversion of a 3-hydroxyalkanoate into said alkene by
(i) a first enzyme having an activity of converting the 3-hydroxyalkanoate into the corresponding 3-phosphonoxyalkanoate; and
(ii) a second enzyme being different from the first enzyme and having an activity of converting said 3-phosphonoxyalkanoate into said a!kene.
The method of claim 1 wherein
(i) the first enzyme having an activity of converting the 3-hydroxyaikanoate into the corresponding 3-phosphonoxyalkanoate is selected from the group consisting of
(A) a protein comprising the amino acid sequence as shown in SEQ ID NO: 1 or a protein comprising an amino acid sequence which is at least 15% identical to the amino acid sequence shown in SEQ ID NO: 1 and showing an activity of converting the 3~ hydroxyalkanoate into the corresponding 3-phosphonoxyalkanoate which is at least as high as the corresponding activity of the protein having the amino acid sequence shown in SEQ ID NO: 1 ;
(B) a protein comprising the amino acid sequence as shown in SEQ ID NO: 2 or a protein comprising an amino acid sequence which is at least 15% identical to the amino acid sequence shown in SEQ ID NO: 2 and showing an activity of converting the 3- hydroxyalkanoate into the corresponding 3-phosphonoxyalkanoate which is at least as high as the corresponding activity of the protein having the amino acid sequence shown in SEQ !D NO: 2;
(C) a protein comprising the amino acid sequence as shown in SEQ ID NO: 3 or a protein comprising an amino acid sequence which is at least 15% identical to the amino acid sequence shown in SEQ ID NO: 3 and showing an activity of converting the 3- hydroxyalkanoate into the corresponding 3-phosphonoxyalkanoate which is at least as high as the corresponding activity of the protein having the amino acid sequence shown in SEQ ID NO: 3; and
(D) a protein comprising the amino acid sequence as shown in SEQ ID NO: 4 or a protein comprising an amino acid sequence which is
at least 15% identical to the amino acid sequence shown in SEQ ID NO: 4 and showing an activity of converting the 3- hydroxyalkanoate into the corresponding 3-phosphonoxyalkanoate which is at least as high as the corresponding activity of the protein having the amino acid sequence shown in SEQ iD NO: 4.
3. The method of claim 1 or 2, wherein
(ii) the second enzyme having an activity of converting said 3- phosphonoxyalkanoate into said alkene selected from the group consisting of
(a) a protein comprising the amino acid sequence as shown in SEQ ID NO: 5 or a protein comprising an amino acid sequence which is at least 15% identica! to the amino acid sequence shown in SEQ ID NO: 5 and showing an activity of converting said 3- phosphonoxyaikanoate into said alkene which is at least as high as the corresponding activity of the protein having the amino acid sequence shown in SEQ ID NO: 5;
(b) a protein comprising the amino acid sequence as shown in SEQ ID NO: 6 or a protein comprising an amino acid sequence which is at least 15% identical to the amino acid sequence shown in SEQ ID NO: 6 and showing an activity of converting said 3- phosphonoxyalkanoate into said alkene which is at least as high as the corresponding activity of the protein having the amino acid sequence shown in SEQ ID NO: 6;
(c) a protein comprising the amino acid sequence as shown in SEQ ID NO: 7 or a protein comprising an amino acid sequence which is at least 15% identical to the amino acid sequence shown in SEQ ID NO: 7 and showing an activity of converting said 3- phosphonoxyaikanoate into said alkene which is at least as high as the corresponding activity of the protein having the amino acid sequence shown in SEQ ID NO: 7;
(d) a protein comprising the amino acid sequence as shown in SEQ ID NO: 8 or a protein comprising an amino acid sequence which is at least 15% identical to the amino acid sequence shown in SEQ ID NO: 8 and showing an activity of converting said 3- phosphonoxyalkanoate into said alkene which is at least as high as the corresponding activity of the protein having the amino acid
sequence shown in SEQ iD NO: 8;
a protein comprising the amino acid sequence as shown in SEQ ID NO: 9 or a protein comprising an amino acid sequence which is at least 15% identical to the amino acid sequence shown in SEQ ID NO: 9 and showing an activity of converting said 3- phosphonoxyalkanoate into said alkene which is at least as high as the corresponding activity of the protein having the amino acid sequence shown in SEQ ID NO: 9
a protein comphsing the amino acid sequence as shown in SEQ ID NO: 10 or a protein comprising an amino acid sequence which is at least 15% identical to the amino acid sequence shown in SEQ ID NO: 10 and showing an activity of converting said 3- phosphonoxyalkanoate into said alkene which is at least as high as the corresponding activity of the protein having the amino acid sequence shown in SEQ ID NO: 10;
a protein comprising the amino acid sequence as shown in SEQ ID NO: 1 1 or a protein comprising an amino acid sequence which is at least 15% identical to the amino acid sequence shown in SEQ ID NO: 1 1 and showing an activity of converting said 3- phosphonoxyalkanoate into said alkene which is at least as high as the corresponding activity of the protein having the amino acid sequence shown in SEQ ID NO: 1 1 ;
a protein comprising the amino acid sequence as shown in SEQ ID NO: 12 or a protein comprising an amino acid sequence which is at least 15% identical to the amino acid sequence shown in SEQ ID NO: 12 and showing an activity of converting said 3- phosphonoxyalkanoate into said alkene which is at least as high as the corresponding activity of the protein having the amino acid sequence shown in SEQ ID NO: 12;
a protein comprising the amino acid sequence as shown in SEQ ID NO: 13 or a protein comprising an amino acid sequence which is at least 15% identical to the amino acid sequence shown in SEQ ID NO: 13 and showing an activity of converting said 3- phosphonoxyaikanoate into said alkene which is at least as high as the corresponding activity of the protein having the amino acid sequence shown in SEQ ID NO: 13;
a protein comprising the amino acid sequence as shown in SEQ
ID NO: 14 or a protein comprising an amino acid sequence which is at least 15% identical to the amino acid sequence shown in SEQ ID NO: 14 and showing an activity of converting said 3- phosphonoxyalkanoate into said alkene which is at ieast as high as the corresponding activity of the protein having the amino acid sequence shown in SEQ ID NO: 14; and
(k) a protein comprising the amino acid sequence as shown in SEQ ID NO: 15 or a protein comprising an amino acid sequence which is at Ieast 15% identical to the amino acid sequence shown in SEQ ID NO: 15 and showing an activity of converting said 3- phosphonoxyalkanoate into said aikene which is at Ieast as high as the corresponding activity of the protein having the amino acid sequence shown in SEQ ID NO: 15.
4. The method of any one of ciaims 1 to 3, comprising the step of converting 3- hydroxyproprionate to ethylene.
5. The method of any one of ciaims 1 to 3, comprising the step of converting 3- hydroxybutyrate to propylene.
6. The method of any one of claims 1 to 3, comprising the step of converting 3- hydroxyvalerate to 1 -butylene.
7. The method of any one of claims 1 to 3, comprising the step of converting 3- hydroxy-3-methyibutyrate to isobutylene.
8. The method of any one of claims 1 to 3, comprising the step of converting 3- hydroxy-3-methyivalerate to isoamylene.
9. The method of any one of the previous claims, characterized in that the conversion step is carried out in vitro, in a cell-free system.
10. The method of any one of the previous claims characterized in that the method is carried out in the presence of a microorganism producing said enzymes as defined in (i) and (ii) of claim 1 .
1 1 . The method of any one of the previous claims, characterized by the use of a
multiceiluiar organism producing said enzymes as defined in (i) and (ii) of claim 1.
12. The method according to any one of the previous claims, comprising a step of collecting gaseous alkenes degassing out of the reaction.
13. A multicellular organism or a microorganism which produces at least two enzymes, wherein one enzyme is selected from (i) and the other enzyme is selected from (ii), wherein (i) and (ii) are as follows:
(i) a first enzyme having an activity of converting the 3-hydroxyalkanoate into the corresponding 3-phosphonoxyalkanoate; and
(ii) a second enzyme being different from the first enzyme and having an activity of converting said 3-phosphonoxyalkanoate into said alkene.
14. A composition comprising the microorganism of claim 13, a suitable culture medium and a 3-hydroxyalkanoate compound or a carbon source that can be converted by the microorganism to a 3-hydroxya!kanoate compound.
15. Use of a combination of at least two enzymes, wherein one enzyme is selected from the following (i) and the other enzyme is selected from the following (ii) or of a microorganism of claim 13 or of a composition of claim 14, for producing alkene compounds from 3-hydroxyalkanoates,
wherein (i) and (ii) are as follows:
(i) a first enzyme having an activity of converting the 3-hydroxyalkanoate into the corresponding 3-phosphonoxyalkanoate; and
(ii) a second enzyme being different from the first enzyme and having an activity of converting said 3-phosphonoxyalkanoate into said alkene.
16. The use of claim 14, wherein
(i) the first enzyme having an activity of converting the 3-hydroxyalkanoate into the corresponding 3-phosphonoxyaikanoate is selected from the group consisting of
(A) a protein comprising the amino acid sequence as shown in SEQ !D NO: 1 or a protein comprising an amino acid sequence which is at least 15% identical to the amino acid sequence shown in SEQ ID NO: 1 and showing an activity of converting the 3- hydroxyalkanoate into the corresponding 3-phosphonoxyalkanoate
which is at least as high as the corresponding activity of the protein having the amino acid sequence shown in SEQ ID NO: 1 ;
(B) a protein comprising the amino acid sequence as shown in SEQ ID NO: 2 or a protein comprising an amino acid sequence which is at least 15% identical to the amino acid sequence shown in SEQ ID NO: 2 and showing an activity of converting the 3- hydroxyalkanoate into the corresponding 3-phosphonoxyalkanoate which is at least as high as the corresponding activity of the protein having the amino acid sequence shown in SEQ ID NO: 2;
(C) a protein comprising the amino acid sequence as shown in SEQ ID NO: 3 or a protein comprising an amino acid sequence which is at least 15% identical to the amino acid sequence shown in SEQ ID NO: 3 and showing an activity of converting the 3- hydroxyalkanoate into the corresponding 3-phosphonoxyalkanoate which is at least as high as the corresponding activity of the protein having the amino acid sequence shown in SEQ ID NO: 3; and
(D) a protein comprising the amino acid sequence as shown in SEQ ID NO: 4 or a protein comprising an amino acid sequence which is at least 15% identical to the amino acid sequence shown in SEQ ID NO: 4 and showing an activity of converting the 3- hydroxyalkanoate into the corresponding 3-phosphonoxyalkanoate which is at least as high as the corresponding activity of the protein having the amino acid sequence shown in SEQ ID NO: 4.
17. The use of claim 15 or 16, wherein
(ii) the second enzyme having an activity of converting said 3- phosphonoxyalkanoate into said alkene selected from the group consisting of
(a) a protein comprising the amino acid sequence as shown in SEQ ID NO: 5 or a protein comprising an amino acid sequence which is at least 15% identical to the amino acid sequence shown in SEQ ID NO: 5 and showing an activity of converting said 3- phosphonoxyalkanoate into said alkene which is at least as high as the corresponding activity of the protein having the amino acid sequence shown in SEQ fD NO: 5;
(b) a protein comprising the amino acid sequence as shown in SEQ
!D NO: 6 or a protein comprising an amino acid sequence which is at ieast 15% identical to the amino acid sequence shown in SEQ ID NO: 6 and showing an activity of converting said 3- phosphonoxyalkanoate into said alkene which is at least as high as the corresponding activity of the protein having the amino acid sequence shown in SEQ ID NO: 6;
a protein comprising the amino acid sequence as shown in SEQ ID NO: 7 or a protein comprising an amino acid sequence which is at ieast 15% identical to the amino acid sequence shown in SEQ ID NO: 7 and showing an activity of converting said 3- phosphonoxyaikanoate into said alkene which is at Ieast as high as the corresponding activity of the protein having the amino acid sequence shown in SEQ ID NO: 7;
a protein comprising the amino acid sequence as shown in SEQ ID NO: 8 or a protein comprising an amino acid sequence which is at Ieast 15% identicai to the amino acid sequence shown in SEQ ID NO: 8 and showing an activity of converting said 3- phosphonoxyalkanoate into said alkene which is at Ieast as high as the corresponding activity of the protein having the amino acid sequence shown in SEQ ID NO: 8;
a protein comprising the amino acid sequence as shown in SEQ ID NO: 9 or a protein comprising an amino acid sequence which is at Ieast 15% identical to the amino acid sequence shown in SEQ ID NO: 9 and showing an activity of converting said 3- phosphonoxyalkanoate into said alkene which is at Ieast as high as the corresponding activity of the protein having the amino acid sequence shown in SEQ ID NO: 9;
a protein comprising the amino acid sequence as shown in SEQ ID NO: 10 or a protein comprising an amino acid sequence which is at Ieast 15% identical to the amino acid sequence shown in SEQ ID NO: 10 and showing an activity of converting said 3- phosphonoxyalkanoate into said alkene which is at !east as high as the corresponding activity of the protein having the amino acid sequence shown in SEQ ID NO: 10;
a protein comprising the amino acid sequence as shown in SEQ ID NO: 1 1 or a protein comprising an amino acid sequence which is at Ieast 15% identical to the amino acid sequence shown in
SEQ ID NO: 1 1 and showing an activity of converting said 3- phosphonoxyalkanoate into said aikene which is at least as high as the corresponding activity of the protein having the amino acid sequence shown in SEQ ID NO: 1 1 ;
(h) a protein comprising the amino acid sequence as shown in SEQ !D NO: 12 or a protein comprising an amino acid sequence which is at least 15% identical to the amino acid sequence shown in SEQ iD NO: 12 and showing an activity of converting said 3- phosphonoxyalkanoate into said aikene which is at least as high as the corresponding activity of the protein having the amino acid sequence shown in SEQ ID NO: 12;
(t) a protein comprising the amino acid sequence as shown in SEQ ID NO: 13 or a protein comprising an amino acid sequence which is at least 15% identical to the amino acid sequence shown in SEQ iD NO: 13 and showing an activity of converting said 3- phosphonoxyalkanoate into said aikene which is at least as high as the corresponding activity of the protein having the amino acid sequence shown in SEQ ID NO: 13;
(j) a protein comprising the amino acid sequence as shown in SEQ ID NO: 14 or a protein comprising an amino acid sequence which is at least 15% identical to the amino acid sequence shown in SEQ ID NO: 14 and showing an activity of converting said 3- phosphonoxyalkanoate into said aikene which is at least as high as the corresponding activity of the protein having the amino acid sequence shown in SEQ ID NO: 14; and
(k) a protein comprising the amino acid sequence as shown in SEQ ID NO: 15 or a protein comprising an amino acid sequence which is at least 15% identical to the amino acid sequence shown in SEQ ID NO: 15 and showing an activity of converting said 3- phosphonoxyalkanoate into said aikene which is at least as high as the corresponding activity of the protein having the amino acid sequence shown in SEQ iD NO: 15.
A method for producing an aikene comprising the step of enzymaticaliy converting a 3-phosphonoxyalkanoate into the corresponding aikene by use of an enzyme which can catalyze the conversion via decarboxylation and dephosphorylation.
The method of any one of claims 1 to 12 or the method of claim 18, characterized in that the method is carried out with ATP, dATP, ADP, AMP, an NTP other than ATP, a dNTP or pyrophosphate as co-substrate.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10188001 | 2010-10-19 | ||
| EP10188001.1 | 2010-10-19 | ||
| PCT/EP2011/068174 WO2012052427A1 (en) | 2010-10-19 | 2011-10-18 | Production of alkenes by combined enzymatic conversion of 3-hydroxyalkanoic acids |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2011317682A1 true AU2011317682A1 (en) | 2013-04-11 |
| AU2011317682B2 AU2011317682B2 (en) | 2015-01-22 |
Family
ID=43734239
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2011317682A Ceased AU2011317682B2 (en) | 2010-10-19 | 2011-10-18 | Production of alkenes by combined enzymatic conversion of 3-hydroxyalkanoic acids |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US9193978B2 (en) |
| EP (1) | EP2630236B1 (en) |
| JP (1) | JP6148619B2 (en) |
| KR (1) | KR101883511B1 (en) |
| CN (1) | CN103261410B (en) |
| AU (1) | AU2011317682B2 (en) |
| BR (1) | BR112013009078A2 (en) |
| CA (1) | CA2813868A1 (en) |
| CO (1) | CO6731070A2 (en) |
| ES (1) | ES2739248T3 (en) |
| GT (1) | GT201300099A (en) |
| IL (1) | IL225549A (en) |
| MX (1) | MX353884B (en) |
| MY (1) | MY156446A (en) |
| PE (1) | PE20140009A1 (en) |
| PH (1) | PH12013500553A1 (en) |
| PL (1) | PL2630236T3 (en) |
| RU (1) | RU2609656C2 (en) |
| SG (1) | SG189185A1 (en) |
| WO (1) | WO2012052427A1 (en) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112013009078A2 (en) * | 2010-10-19 | 2016-07-19 | Global Bioenergies | production of alkenes by combined enzymatic conversion of 3-hydroxyalkanoic acids |
| US9422578B2 (en) | 2011-06-17 | 2016-08-23 | Invista North America S.A.R.L. | Methods for biosynthesizing 1,3 butadiene |
| US9663801B2 (en) | 2011-06-17 | 2017-05-30 | Invista North America S.A.R.L. | Methods of producing four carbon molecules |
| EP2794891A2 (en) * | 2011-12-20 | 2014-10-29 | Scientist of Fortune S.A. | Production of 1,3-dienes by enzymatic conversion of 3-hydroxyalk-4-enoates and/or 3-phosphonoxyalk-4-enoates |
| DE102012105877A1 (en) | 2012-07-02 | 2014-01-02 | Oxea Gmbh | Process for the preparation of diisobutene |
| DE102012105879A1 (en) | 2012-07-02 | 2014-01-02 | Oxea Gmbh | Process for the preparation of isononyl derivatives |
| DE102012105876A1 (en) | 2012-07-02 | 2014-01-02 | Oxea Gmbh | Process for the preparation of terephthalic acid and its derivatives |
| DE102012105874A1 (en) | 2012-07-02 | 2014-01-02 | Oxea Gmbh | Process for the preparation of vinyl isononanoates |
| DE102012105878A1 (en) | 2012-07-02 | 2014-01-02 | Oxea Gmbh | Process for the preparation of isopentane derivatives |
| US9803220B2 (en) | 2012-10-25 | 2017-10-31 | Global Bioenergies | Production of alkenes from 3-hydroxy-1-carboxylic acids via 3-sulfonyloxy-1-carboxylic acids |
| EP2925871A1 (en) | 2012-11-28 | 2015-10-07 | Invista Technologies S.A R.L. | Methods for biosynthesis of isobutene |
| AU2013354179B2 (en) | 2012-12-07 | 2018-10-18 | Global Bioenergies | Improved fermentation method |
| US20150329878A1 (en) * | 2012-12-07 | 2015-11-19 | Global Bioenergies | Fermentative production of a hydrocarbon |
| PL3019604T3 (en) * | 2013-07-09 | 2021-01-25 | Global Bioenergies | Mevalonate diphosphate decarboxylase variants |
| US10294496B2 (en) | 2013-07-19 | 2019-05-21 | Invista North America S.A.R.L. | Methods for biosynthesizing 1,3 butadiene |
| EP3030667A2 (en) | 2013-08-05 | 2016-06-15 | Invista Technologies S.a r.l. | Methods for biosynthesis of isoprene |
| US10533193B2 (en) | 2013-08-05 | 2020-01-14 | Invista North America S.A.R.L. | Methods for biosynthesis of isobutene |
| EP3155112A1 (en) | 2014-06-16 | 2017-04-19 | Invista Technologies S.à.r.l. | Process for producing glutarate and glutaric acid methyl ester |
| WO2017017124A1 (en) | 2015-07-28 | 2017-02-02 | Global Bioenergies | Hiv kinase variants |
| WO2019006255A1 (en) | 2017-06-30 | 2019-01-03 | Invista North America S.A.R.L. | Methods, materials, synthetic hosts and reagents for the biosynthesis of hydrocarbons and derivatives thereof |
| US11162115B2 (en) | 2017-06-30 | 2021-11-02 | Inv Nylon Chemicals Americas, Llc | Methods, synthetic hosts and reagents for the biosynthesis of hydrocarbons |
| US11505809B2 (en) | 2017-09-28 | 2022-11-22 | Inv Nylon Chemicals Americas Llc | Organisms and biosynthetic processes for hydrocarbon synthesis |
| EP3502216A1 (en) | 2017-12-21 | 2019-06-26 | Global Bioenergies | Gasoline composition enabling reduced particulate emissions |
| BR112020018799A2 (en) | 2018-03-16 | 2021-03-23 | Fina Technology, Inc. | polymeric composition and use for producing adhesive and article containing it |
| WO2019175393A1 (en) | 2018-03-16 | 2019-09-19 | Total Raffinage Chimie | Preparation of olefin by alcohol dehydration, and uses thereof for making polymer, fuel or fuel additive. |
| BR112021000598A2 (en) | 2018-07-27 | 2021-04-13 | Global Bioenergies | METHOD TO PRODUCE FRUCTOSE-6-PHOSPHATE, RECOMBINANT MICRO-ORGANISM, ENZYME COMBINATION, COMPOSITION AND USE OF THE MICRO-ORGANISM |
| CN109251940B (en) * | 2018-10-30 | 2020-10-16 | 浙江华睿生物技术有限公司 | Construction method of engineering bacteria for producing beta-hydroxy-beta-methylbutyric acid |
| EP3908663A1 (en) | 2019-02-20 | 2021-11-17 | Braskem S.A. | Microorganisms and methods for the production of oxygenated compounds from hexoses |
| WO2020168408A1 (en) | 2019-02-20 | 2020-08-27 | Braskem S.A. | Degradation pathway for pentose and hexose sugars |
| EP3942058A1 (en) | 2019-03-20 | 2022-01-26 | Global Bioenergies | Improved means and methods for producing isobutene from acetyl-coa |
| FR3099931B1 (en) | 2019-08-16 | 2021-11-12 | Global Bioenergies | Branched and functionalized alkanes and their preparation process |
| FR3099930A1 (en) | 2019-08-16 | 2021-02-19 | Global Bioenergies | CARBONYL COMPOUNDS, THEIR PREPARATION METHODS AND THEIR USES |
| FR3108606A1 (en) | 2020-03-27 | 2021-10-01 | Global Bioenergies | Branched olefins and their preparation process |
| CN114502523A (en) | 2019-08-16 | 2022-05-13 | 欧莱雅 | Branched alkanes and process for their preparation |
| FR3099929B1 (en) | 2019-08-16 | 2024-02-16 | Global Bioenergies | ESTERIFIED OR ETHERIFIED COMPOUNDS, THEIR PREPARATION PROCESSES AND THEIR USES |
| FR3099928B1 (en) | 2019-08-16 | 2021-07-30 | Global Bioenergies | Branched alkanes and their preparation process |
| EP3792234A1 (en) | 2019-09-16 | 2021-03-17 | Total Raffinage Chimie | Method for the preparation of 2-methyl-but-2-ene |
| WO2021063958A1 (en) | 2019-09-30 | 2021-04-08 | Global Bioenergies | Improved means and methods for increasing the yield of acetyl-coa from glucose |
| FR3108608A1 (en) | 2020-03-27 | 2021-10-01 | Global Bioenergies | Functionalized branched olefins and their preparation process |
| FR3110081B1 (en) | 2020-05-14 | 2022-09-09 | Global Bioenergies | Cosmetic composition based on biosourced isododecane and process for its preparation |
| FR3112477B1 (en) | 2020-07-15 | 2022-08-26 | Global Bioenergies | Cosmetic composition based on isododecane with a high content of 2,2,4,6,6-pentamethylheptane |
| FR3115988A1 (en) | 2020-11-06 | 2022-05-13 | Global Bioenergies | Make-up composition based on biosourced isododecane and process for its preparation |
| JP2023554488A (en) | 2020-12-21 | 2023-12-27 | グローバル・バイオエナジーズ | Improved means and methods for producing isobutene from 3-methylcrotonic acid |
| WO2022171871A1 (en) | 2021-02-15 | 2022-08-18 | Global Bioenergies | Alkylphenols, methods for the production thereof, and uses thereof |
| WO2022171887A1 (en) | 2021-02-15 | 2022-08-18 | Global Bioenergies | Substituted alkyl(thio)phenols, processes for producing same, and uses thereof |
| EP4399284A1 (en) | 2021-09-06 | 2024-07-17 | Global Bioenergies | Organisms producing less crotonic acid |
| EP4144838A1 (en) | 2021-09-06 | 2023-03-08 | Global Bioenergies | Organisms producing less crotonic acid |
| FR3157389A1 (en) | 2023-12-22 | 2025-06-27 | Axens | Process for producing bioalkylate or bio-sourced gasoline |
| WO2025226576A1 (en) | 2024-04-25 | 2025-10-30 | ExxonMobil Technology and Engineering Company | Processes for producing isobutylene and isobutylene-based polymers |
| WO2026003122A1 (en) | 2024-06-26 | 2026-01-02 | Global Bioenergies | Method for producing isobutene from acetic acid |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6192579A (en) | 1984-10-09 | 1986-05-10 | Hideo Fukuda | Production of hydrocarbon mixture |
| JPH067798B2 (en) * | 1985-06-06 | 1994-02-02 | 秀雄 福田 | Microbial production of ethylene |
| KR100470192B1 (en) * | 1996-06-27 | 2005-10-04 | 리간드 파마슈티칼스 인코포레이티드 | Androgen Receptor Modulators Compounds and Methods |
| US6989257B2 (en) | 2001-06-06 | 2006-01-24 | Dsm Ip Assets B.V. | Isoprenoid production |
| US7309487B2 (en) | 2004-02-09 | 2007-12-18 | George Inana | Methods and compositions for detecting and treating retinal diseases |
| WO2006018211A1 (en) | 2004-08-19 | 2006-02-23 | Dsm Ip Assets B.V. | Production of isoprenoids |
| RU2281316C1 (en) * | 2005-05-05 | 2006-08-10 | Вадим Алексеевич Меньщиков | Ethylene production process |
| ES2647785T3 (en) * | 2008-07-04 | 2017-12-26 | Scientist Of Fortune S.A. | Production of alkenes by enzymatic decarboxylation of 3-hydroxy-alkanoic acids |
| BRPI0922944A2 (en) * | 2008-12-12 | 2015-08-25 | Celexion Llc | Metabolically engineered host cell for the production of an alkane, containing one or more exogenous nucleic acid sequences and method for producing an alkane |
| BR112013009078A2 (en) * | 2010-10-19 | 2016-07-19 | Global Bioenergies | production of alkenes by combined enzymatic conversion of 3-hydroxyalkanoic acids |
-
2011
- 2011-10-18 BR BR112013009078A patent/BR112013009078A2/en not_active Application Discontinuation
- 2011-10-18 CA CA2813868A patent/CA2813868A1/en not_active Abandoned
- 2011-10-18 EP EP11784957.0A patent/EP2630236B1/en active Active
- 2011-10-18 WO PCT/EP2011/068174 patent/WO2012052427A1/en not_active Ceased
- 2011-10-18 US US13/880,042 patent/US9193978B2/en active Active
- 2011-10-18 MY MYPI2013001094A patent/MY156446A/en unknown
- 2011-10-18 RU RU2013122680A patent/RU2609656C2/en not_active IP Right Cessation
- 2011-10-18 PL PL11784957T patent/PL2630236T3/en unknown
- 2011-10-18 JP JP2013534290A patent/JP6148619B2/en active Active
- 2011-10-18 AU AU2011317682A patent/AU2011317682B2/en not_active Ceased
- 2011-10-18 MX MX2013004431A patent/MX353884B/en active IP Right Grant
- 2011-10-18 ES ES11784957T patent/ES2739248T3/en active Active
- 2011-10-18 KR KR1020137010140A patent/KR101883511B1/en not_active Expired - Fee Related
- 2011-10-18 SG SG2013023940A patent/SG189185A1/en unknown
- 2011-10-18 PE PE2013000867A patent/PE20140009A1/en active IP Right Grant
- 2011-10-18 PH PH1/2013/500553A patent/PH12013500553A1/en unknown
- 2011-10-18 CN CN201180050057.7A patent/CN103261410B/en active Active
-
2013
- 2013-04-04 IL IL225549A patent/IL225549A/en active IP Right Grant
- 2013-04-16 GT GT201300099A patent/GT201300099A/en unknown
- 2013-04-18 CO CO13100240A patent/CO6731070A2/en unknown
-
2015
- 2015-10-19 US US14/886,437 patent/US20160032326A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9193978B2 (en) | Production of alkenes by combined enzymatic conversion of 3-hydroxyalkanoic acids | |
| AU2011317682A1 (en) | Production of alkenes by combined enzymatic conversion of 3-hydroxyalkanoic acids | |
| AU2009265373B2 (en) | Production of alkenes by enzymatic decarboxylation of 3-hydroxyalkanoic acids | |
| US9873895B2 (en) | Production of 1,3-dienes by enzymatic conversion of 3-hydroxyalk 4-enoates and/or 3-phosphonoxyalk-4-enoates | |
| JP6513022B2 (en) | Production of volatile dienes by enzymatic dehydration of light alkenols | |
| EP2336341A1 (en) | Method for producing an alkene comprising the step of converting an alcohol by an enzymatic dehydration step | |
| WO2016042012A1 (en) | Methods for producing 3-hydroxy-3-methylbutyric acid | |
| CN105940111B (en) | Preparation of olefins from 3-hydroxycarboxylic acids via 3-hydroxycarboxyl-nucleosidic acids | |
| TW201723170A (en) | Arginine supplementation for improving the efficiency of gas fermentation of acetic acid producing bacteria | |
| MX2012008179A (en) | Production of hydrocarbons in microorganisms. | |
| WO2026003122A1 (en) | Method for producing isobutene from acetic acid |